aspirin has been researched along with ticagrelor in 569 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (2.11) | 29.6817 |
| 2010's | 308 (54.13) | 24.3611 |
| 2020's | 249 (43.76) | 2.80 |
| Authors | Studies |
|---|---|
| Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M | 1 |
| Gurbel, PA; Tantry, US | 1 |
| Roe, MT; Steinhubl, S | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF | 1 |
| Barker, CM; Price, MJ | 1 |
| Angiolillo, DJ; Guzman, LA | 1 |
| Eikelboom, JW; Hirsh, J; Raju, NC | 1 |
| Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Kumar, A; Roberts, DH | 1 |
| Collet, JP; Montalescot, G | 1 |
| Antonino, MJ; Bliden, KP; Butler, K; Gesheff, T; Gurbel, PA; Karunakaran, A; Kereiakes, DJ; Ledley, GS; Parris, C; Patil, SB; Purdy, D; Storey, RF; Tantry, US; Teng, R; Wei, C; Wilson, V | 1 |
| Aylward, PE; Behan, MW; Chew, DP | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Storey, RF | 1 |
| Chew, DP; Prakash, R; Wong, YW | 1 |
| Erdem, G; Flather, MD; Geisler, T | 1 |
| Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS | 1 |
| Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C | 1 |
| Gratsianskiĭ, NA | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| Abergel, E; Nikolsky, E | 1 |
| Pollack, CV | 1 |
| Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C | 1 |
| Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C | 1 |
| Frey, N; Ivandic, B | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Buffet, P; Cottin, Y; Gudjoncik, A; L'Huillier, I; Lorgis, L; Richard, C; Zeller, M | 1 |
| Gaglia, MA; Waksman, R | 1 |
| Cattaneo, M | 1 |
| Hamm, CW; Rassaf, T | 1 |
| Serebruany, VL | 2 |
| White, HD | 1 |
| Berger, PB; Good, CW | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Bliden, KP; Gesheff, M; Gurbel, PA; Jeong, YH; Storey, RF; Tantry, US; Wei, C | 1 |
| Hinneburg, I | 1 |
| Chan, MV; Kirkby, NS; Leadbeater, PD; Mitchell, JA; Nylander, S; Warner, TD | 1 |
| Traynor, K | 1 |
| Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J | 2 |
| Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Jeger, R; Kaiser, C; Pfisterer, M | 1 |
| Braunwald, E | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Lavi, R; Lavi, S | 1 |
| Angiolillo, DJ; Azmoon, S | 1 |
| Heptinstall, S; Joshi, R; Wijeyeratne, YD | 1 |
| Ahmad, S; Storey, RF | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A | 1 |
| Huber, K | 1 |
| Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A | 1 |
| Kiss, RG | 1 |
| Butler, K; Maya, J; Teng, R | 1 |
| Htun, WW; Steinhubl, SR | 1 |
| Asanin, M; Brdar, N; Cvetinovic, N; Djuricic, N; Krljanac, G; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L; Stankovic, S; Stojanovic, M | 1 |
| Aronow, WS | 1 |
| Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H | 1 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| DiNicolantonio, JJ; Serebruany, VL | 1 |
| James, S | 1 |
| Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C | 1 |
| Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US | 1 |
| Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K | 1 |
| DiNicolantonio, JJ; Serebruany, VL; Tomek, A | 1 |
| Berger, JS | 1 |
| Fabiszak, T; Grzesk, E; Grześk, G; Gurbel, PA; Jeong, YH; Kozinski, M; Kubica, J; Navarese, EP; Tantry, US; Wicinski, M | 1 |
| Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL | 1 |
| Dinicolantonio, JJ; Norgard, NB | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Grove, EL; Würtz, M | 2 |
| Clavijo, L; Gaglia, MA | 1 |
| Curkovic, I; Egbring, M; Kullak-Ublick, GA | 1 |
| Gasche, D; Greiner, RA; Meier, B; Ulle, T | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| Adsett, G; Jayasinghe, R; Markham, R | 1 |
| Albertsson, P; Åström-Olsson, K; Dellborg, M; Hansson, EC; Hesse, C; Jeppsson, A; Shams Hakimi, C; Wallén, H | 1 |
| Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M | 1 |
| Bauer, M; Bräuer, A; Danner, BC; Hinz, J; Meyer, K; Mohite, PN; Popov, AF; Schöndube, FA; Schotola, H; Sossalla, S | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Hirschl, MM | 1 |
| Cheng, VE; Haikerwal, D; Natarajan, D; Oppermen, A; Pereira, J | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Diamantopoulos, A; Karnabatidis, D; Katsanos, K; Kitrou, P; Pastromas, G; Siablis, D; Spiliopoulos, S | 1 |
| Edwards, MG; O'Shea, JP; Starac, D; Waterer, GW; Whitmore, TJ | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Jensen, EC; Sabatine, MS; Steg, PG; Storey, RF | 1 |
| Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D | 1 |
| Er Ching, M; Ho, HH; Ong, PJ; Ooi, YW | 1 |
| Bangalore, S; Biondi-Zoccai, G; Cerrato, E; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Fuchs, FD; Lavie, CJ; Meier, P; Niazi, AK; Norgard, NB; O'Keefe, JH; Packard, KA; Serebruany, VL | 1 |
| Droppa, M; Gawaz, M; Geisler, T; Karathanos, A; Metzger, J; Müller, K; Rath, D; Schäffeler, E; Schwab, M; Stimpfle, F; Tavlaki, E; Winter, S | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Gensini, GF; Giurlani, L; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Emanuelsson, H; Hiasa, Y; Teng, R | 1 |
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
| Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E | 1 |
| Baber, U; Badimon, JJ; Crippa, M; Giannarelli, C; Mehran, R; Rodriguez, D; Sartori, S; Tewar, MP; Vorchheimer, DA; Zafar, MU | 1 |
| Adlam, D; Choudhury, RP; Hadley, G; Harrison, P | 1 |
| Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P | 1 |
| Fauchère, I; Schreiber, P; Wyss, C | 1 |
| Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M | 1 |
| Vengoechea, F | 1 |
| Dankiewicz, J; Friberg, H; Kander, T; Schött, U | 1 |
| Agostoni, P; Stella, PR; Timmers, L | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Brokopp, J; Erlinge, D; Kander, T; Lood, C; Schött, U | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H | 1 |
| Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P | 1 |
| Cho, JH; Ihm, CG; Jeong, KH; Kim, JB; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS | 1 |
| Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S | 1 |
| Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD | 1 |
| Keaney, JF | 1 |
| Steg, PG; Wiviott, SD | 1 |
| Kafkas, NV; Liakos, CI; Mouzarou, AG | 1 |
| Heitmeier, S; Laux, V; Perzborn, E | 1 |
| Aspromonte, N; Caldarola, P; Chiatto, M; Iacoviello, M; Monitillo, F; Valle, R | 1 |
| Ciccone, A; Mariani, R; Marinangeli, F | 1 |
| Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH | 1 |
| Al-Kindi, SG; Benatti, RD; Deo, S; ElAmm, C; Ginwalla, M; Medalion, B; Oliveira, GH; Osman, MN; Park, SJ; Qattan, MY; Simon, DI | 1 |
| Gao, F; Liu, XL; Shen, H; Wang, ZJ; Yang, SW; Zhou, YJ | 1 |
| Bonhomme, F; Cartier Faessler, V; Fontana, P; Maillard, J | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 6 |
| Andersson, M; Gustafsson, D; Nylander, S; Skärby, T; Wågberg, F | 1 |
| Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R | 1 |
| Guimarães, PO; Tricoci, P | 1 |
| Ahmed, Z; Bajwa, A; Bhardwaj, B; Laster, SB; Magalski, A | 1 |
| Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M | 1 |
| Buccheri, S; Capodanno, D; Capranzano, P; Tamburino, C | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wong, LK | 1 |
| Chen, Y; Cong, H; Dong, W; Hong, T; Li, Z; Wan, Z; Yin, T | 1 |
| Bachelot-Loza, C; Berndt, C; Calmette, L; Decouture, B; Gaussem, P; Godier, A; Gouin-Thibault, I; Martin, AC; Philip, I; Samama, CM | 1 |
| Al Khalifa, A; Al Shouli, S; Bonneau, C; Chung, J; Currie, ME; Fagan, A; Lee, MM; Mewhort, HE; Ruel, M; Teoh, H; Verma, S; White, CW; Yamashita, MH; Yanagawa, B | 1 |
| Borghesi, M; D'Amico, G; Musumeci, G; Parodi, G; Tarantini, G | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Suryapranata, H; Verdoia, M | 1 |
| Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL | 1 |
| Choi, JH; Chon, MK; Chun, KJ; Han, DC; Han, J; Hwang, J; Hwang, KW; Jeong, YH; Kim, CH; Kim, IS; Kim, JH; Kim, JS; Lee, SH; Lee, SM; Lee, SY; Noh, M; Park, DW; Park, YH; Sohn, CB | 1 |
| Garcia-Garcia, HM; Hamm, C; Jüni, P; Serruys, PW; Steg, PG; Valgimigli, M; van Es, GA; Vranckx, P; Windecker, S | 1 |
| Jacquemyn, Y; Mannaerts, D; Muys, J; Verbruggen, M | 1 |
| Bougouin, W; Cariou, A; Dumas, F; Gouffran, G; Jakamy, R; Joffre, J; Lamhaut, L; Rosencher, J; Varenne, O | 1 |
| Dobesh, PP; Doyle, M; Varnado, S | 1 |
| Eichinger, S; Kaider, A; Kollars, M; Kyrle, PA; Traby, L; Wolzt, M | 1 |
| Chava, S; Schneider, DJ | 1 |
| Abacı, A; Aygencel, G; Kara, İ; Okuyan, H; Türkoğlu, M; Yıldırım, F | 1 |
| Parker, WA; Storey, RF | 1 |
| Bernstein, V; Cairns, J; Mancini, GB; Mayo, J; Saw, J; Skarsgard, P; Starovoytov, A; Wong, GC; Ye, J | 1 |
| Cherian, T; Devlin, G; Green, SA; Lee, M | 1 |
| Chong Tou, TJ; Lei Put, PZ; Lei Sio, ZW; Lei Sok, SM; Liu, PM; O U, YF; Sio Cham, ZC; Wang, JF; Wu, W; Zhou, SX | 1 |
| Geissel, W | 1 |
| Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R | 1 |
| Aggarwal, N; Angiolillo, DJ; Antoun, P; Bass, TA; Been, L; Cho, JR; Durairaj, A; Faz, GT; Franchi, F; Guzman, LA; Hu, J; Kureti, M; Park, Y; Rollini, F; Suryadevara, S; Thano, E; Zenni, MM | 1 |
| Carlson, GF; Guo, J; Li, H; Teng, R | 1 |
| Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF | 1 |
| Ruiz-Nodar, JM | 1 |
| Dégano, IR; Elosua, R; Grau, M; Marrugat, J; Sayols-Baixeras, S | 1 |
| Bonello, L; Dignat-Georges, F; Fromonot, J; Guieu, R; Kipson, N; Mottola, G; Paganelli, F; Rossi, P; Ruf, J | 1 |
| Katsi, V; Tousoulis, D; Toutouzas, K; Trantalis, G | 1 |
| Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS | 2 |
| Broe, A; Diness, TG; Emneus, M; Gislason, GH; Green, A; Hasvold, P; Pottegård, A | 1 |
| de Mol, BA; Li, WW; Manshanden, JS; Schotborgh, MA; Tomšič, A | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D | 1 |
| Chung, SC; Denaxas, S; Emmas, C; Hemingway, H; Moayyeri, A; Pasea, L; Pujades-Rodriguez, M; Rapsomaniki, E; Shah, AD; Stogiannis, D; Timmis, A | 1 |
| Goudevenos, JA; Ntalas, IV; Tatsidou, PT; Tselepis, AD; Tsoumani, ME | 1 |
| Cattaneo, M; Cipriani, M; Femia, EA; Frigerio, M; Morici, N; Oliva, F; Perna, E | 1 |
| Gearman, DJ; Ingimarsson, JP; Krambeck, AE; Scales, J; Sharma, V; Westerman, ME | 1 |
| Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
| Wise, J | 1 |
| Priglinger, ML | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF | 1 |
| Attmann, T; Beyersdorf, F; Boening, A; Cremer, J; Danner, BC; de Waha, A; Fischlein, T; Goerlach, G; Hambrecht, R; Hamm, C; Hammel, D; Joost, A; Kastrati, A; Knosalla, C; Koch-Buettner, K; Lange, R; Laufer, G; Misfeld, M; Mohr, FW; Oberhoffer, M; Putman, LM; Radke, PW; Sandner, S; Schmoeckel, M; Schöndube, FA; Schönrath, F; Schulz, R; Schunkert, H; Siepe, M; Sievers, HH; von Scheidt, M; Walther, T; Zeymer, U; Ziegelhöffer, T | 1 |
| Barillà, F; Borzi, M; Camici, P; Cas, LD; Di Biase, M; Filardi, PP; Indolfi, C; Mercuro, G; Montemurro, V; Padeletti, L; Pelliccia, F; Romeo, F; Vizza, CD | 1 |
| Bancone, C; Biancari, F; Chocron, S; Dalén, M; De Feo, M; Dominici, C; Faggian, G; Fischlein, T; Gatti, G; Gherli, R; Gherli, T; Gulbins, H; Kinnunen, EM; Mariscalco, G; Maschietto, L; Maselli, D; Mignosa, C; Musumeci, F; Nicolini, F; Onorati, F; Perrotti, A; Reichart, D; Rosato, S; Rubino, AS; Ruggieri, VG; Santarpino, G; Santini, F; Svenarud, P; Verhoye, JP; Zanobini, M | 1 |
| Bianco, D; Brunelli, C; Chiarella, F; Massobrio, L; Rosa, GM; Valbusa, A | 1 |
| Gurbel, PA; Kubica, J; Myat, A; Tantry, US | 1 |
| Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC | 1 |
| Angiolillo, DJ; Aquino, M; Baber, U; Badimon, J; Chandrasekhar, J; Cohen, DJ; Dangas, G; Gibson, CM; Kastrati, A; Krucoff, MW; Mehran, R; Mehta, SR; Ohman, EM; Pocock, SJ; Sartori, S; Steg, PG; Zafar, MU | 1 |
| Kola, N; Mattiello, G; Mirra, M; Morisco, C; Spinelli, L | 1 |
| Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J | 1 |
| Barbour, C; Gesheff, T | 1 |
| Avgerinos, E; Bakoyiannis, C; Moris, D | 1 |
| Johnston, SC; Wang, Y | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL | 2 |
| Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M | 1 |
| Coons, JC; Iasella, CJ; Kane-Gill, SL; Verlinden, NJ | 1 |
| Armstrong, PC; Chan, MV; Ferreira, PM; Hayman, MA; Hoefer, T; Knowles, RB; Tucker, AT; Warner, TD | 1 |
| Wood, H | 1 |
| Almquist, J; Gennemark, P; Goodman, J; Janefeldt, A; Johansson, KJ; Maqbool, S; Nylander, S; Pehrsson, S; Sanchez, J; Sandinge, AS | 1 |
| Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J | 1 |
| Carr, K; Ghamasaee, P; Grandhi, R; Johnson, J | 1 |
| Becker, RC; Cannon, CP; Hagström, E; Himmelmann, A; James, SK; Katus, HA; Lindholm, D; López-Sendón, JL; Maurer, G; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Eichelberger, B; Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Panzer, S; Pultar, J; Seidinger, D; Wadowski, PP | 1 |
| Bellomo, G; Carriero, A; Daffara, V; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Verdoia, M | 1 |
| Van de Werf, F | 1 |
| Baber, U; Vogel, B | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V | 1 |
| Godier, A; Houssany-Pissot, S; Martin, AC; Taylor, G; Zlotnik, D | 1 |
| Han, X; Jing, Q; Li, R; Tang, X; Wang, Q; Yang, M; Yu, X; Zhao, J | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Himmelmann, A; Huber, K; James, SK; Katus, HA; Lowenstern, A; Morais, J; Neely, M; Siegbahn, A; Steg, PG; Storey, RF; Sun, JL; Wallentin, L | 1 |
| Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y | 1 |
| Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R | 1 |
| Bachelot-Loza, C; Belleville-Rolland, T; Gaussem, P; Godier, A; Helley, D; Martin, AC | 1 |
| Barrio, M; Do, B; Faucheron, A; Karoui, M; Rietveld, IB; Sadou Yayé, H; Secrétan, PH; Tilleul, P; Yagoubi, N | 1 |
| Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL | 1 |
| de Mast, Q; El Messaoudi, S; Gerretsen, J; Gomes, M; Kiers, D; Kox, M; Pickkers, P; Riksen, NP; Rongen, GA; van der Heijden, WA; van der Ven, AJ; van Ede, L | 1 |
| Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL | 1 |
| Budaj, A; Ramotowski, B; Żuk, A | 1 |
| Anuwatworn, A; Kumar, V; Petrasko, M; Stys, A; Yee, J | 1 |
| Giedraitiene, A; Jakstas, V; Kupstyte, N; Lesauskaite, V; Skipskis, V; Tatarunas, V; Zvikas, V | 1 |
| Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Diallo, A; Fabris, E; Goodman, SG; Hamm, CW; Hammett, CJ; Huber, K; Janzon, M; Kerneis, M; Lapostolle, F; Lassen, JF; Merkely, B; Montalescot, G; Storey, RF; Ten Berg, JM; Tsatsaris, A; van 't Hof, A; Vicaut, E; Zeymer, U | 1 |
| Bhatt, DL; Cannon, CP; Ellis, SG; Gropper, S; Harper, R; Hohnloser, SH; Januzzi, JL; Kimura, T; Kleine, E; Lip, GYH; Maeng, M; Manassie, J; Merkely, B; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Zeymer, U | 1 |
| Benfatto, G; Drago, F; Gozzo, L; Longo, L; Mansueto, S; Navarria, A; Pani, L; Salomone, S; Sottosanti, L | 1 |
| Bluestein, D; Consolo, F; Dimasi, A; Fiore, GB; Rasponi, M; Redaelli, A; Slepian, MJ | 1 |
| Brugaletta, S; Campo, G; Cortese, B; Geraci, S; Ielasi, A; Ishida, K; Latib, A; Nicolini, E; Poli, A; Rapetto, C; Scotto di Uccio, F; Secco, GG; Tespili, M; Varricchio, A; Vicinelli, P | 1 |
| Cho, JY; Hong, SJ; Joo, HJ; Kim, KA; Lee, SH; Lim, DS; Park, JH; Park, JY; Yu, CW | 1 |
| Abu-Much, A; Asher, E; Barbash, I; Beigel, R; Chernomordik, F; Elian, D; Fefer, P; Guetta, V; Katz, M; Matetzky, S; Mazin, I; Narodistky, M; Regev, E; Sabbag, A; Segev, A; Tal, S | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cavallari, I; Cohen, M; Creager, MA; Goodrich, EL; Morrow, DA; Olin, J; Piazza, G; Sabatine, MS; Scirica, BS; Steg, PG; Storey, RF | 1 |
| Baos, S; Baumbach, A; Bowles, R; Culliford, L; Johnson, T; Mumford, A; Reeves, BC; Rogers, CA; Underwood, W | 1 |
| Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C | 1 |
| Jia, P; Wang, XF; Ye, M; Zeng, YJ | 1 |
| Landmesser, U; Stähli, BE | 1 |
| Bryniarski, K; Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Li, L; Liu, H; Ma, L; Sugiyama, T; Wang, C; Xing, L; Xu, M; Yamamoto, E; Yu, B; Zhang, S; Zhu, Y | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Deharo, P; Fernandez, M; Fourcade, L; Ibrahim, M; Johnson, TW; Morange, PE; Quilici, J; Suchon, P; Verdier, V | 1 |
| Armstrong, PC; Chan, MV; Egelund, J; Gliemann, L; Hellsten, Y; Lundberg Slingsby, MH; Rytter, N; Thrane, M; Warner, TD | 1 |
| Åkerblom, A; Aukrust, P; Becker, RC; Bertilsson, M; Ghukasyan, T; Himmelmann, A; James, SK; Kontny, F; Michelsen, AE; Siegbahn, A; Storey, RF; Ueland, T; Wallentin, L | 1 |
| Armstrong, N; Duffy, S; Joore, MA; Kleijnen, J; Lang, S; Pouwels, XGLV; Ramaekers, BLT; Ryder, S; Van Giessen, A; Wolff, R; Worthy, G | 1 |
| Barbieri, L; Bellomo, G; Carriero, A; De Luca, G; Kedhi, E; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Aga, U; Atalay, B; Doganay, O; Karadag, E; Tugrul, M | 1 |
| Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y | 1 |
| Amelot, A; Angoulvant, D; Bibi, R; Gruel, Y; Herbreteau, D; Janot, K; Narata, AP | 1 |
| Ahn, Y; Chae, IH; Chae, JK; Chae, SC; Cho, MC; Han, JK; Hur, SH; Jeong, MH; Kang, HJ; Kang, J; Kim, HS; Kim, YJ; Koo, BK; Park, KW; Seong, IW; Seung, KB; Yang, HM | 1 |
| Abenhaim, L; Benichou, J; Bonello, L; Cottin, Y; Dallongeville, J; Danchin, N; Delarche, N; Falissard, B; Furber, A; Ghanem, F; Grimaldi-Bensouda, L; Leclercq, F; Morel, O; Puymirat, E | 1 |
| Abreu, AM; Boronat, V; Kouchoukos, NT; Kulik, A; Ruel, M | 3 |
| Fonarow, GC; Ge, J; Han, Y; Hao, Y; Huo, Y; Liu, J; Ma, C; Morgan, L; Nie, S; Smith, SC; Taubert, KA; Wang, X; Zhao, D; Zhao, G; Zhou, M | 1 |
| Bhalla, NP; Hiatt, WR; Jones, WS; Khan, ND; Low Wang, CC; Patel, MR; Rogers, RK; Shishehbor, MH; White, R | 1 |
| Chen, X; Cheng, Z; Mei, J; Wang, X; Xu, Z; Zhao, Q; Zhu, Y | 1 |
| Hally, KE; Harding, SA; La Flamme, AC; Larsen, PD | 1 |
| Alam, M; Ballantyne, CM; Basra, SS; Bozkurt, B; Chiswell, K; Denktas, AE; Deswal, A; Jneid, H; Nambi, V; Peterson, ED; Simon, DN; Virani, SS; Wang, TY | 1 |
| Brignardello-Petersen, R | 1 |
| Dawood, BB; Hayes, J; Hoskins, HC; Protty, MB; Wilkins, SJ | 1 |
| Dannenberg, L; Dimitroulis, D; Golabkesh, M; Helten, C; Jung, C; Kelm, M; Knoop, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T | 1 |
| Chen, Q; Cho, DJ; Lee, ML; Najera, SD; Rosenson, RS | 1 |
| Calnan, MW; Crawford, AN | 1 |
| Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A | 1 |
| Niu, P; Ouyang, S; Xiao, M; Zhuo, B; Zhuo, X | 1 |
| Calabria, S; Cimminiello, C; Dondi, L; Maggioni, AP; Martini, N; Pedrini, A; Ronconi, G | 1 |
| Le Bras, A | 1 |
| Gissel, MS; Jakobsen, CJ; Jensen, MJ; Kremke, M; Thomassen, SA | 1 |
| Garcia-Garcia, HM; Shlofmitz, E | 1 |
| Du, Y; Liu, W; Yan, ZX; Zhang, JW; Zhao, YX; Zhou, YJ | 1 |
| Chang, CC; Chen, SM; Chen, YC; Cheng, SM; Chuang, CL; Lin, FY; Lin, RH; Lin, YW; Sheu, JS; Tsai, CS | 2 |
| Barlow, CW; Sadeque, SA | 1 |
| Farag, M; Gorog, DA; Gue, YX; Spinthakis, N; Srinivasan, M; Wellsted, DM | 1 |
| Diao, X; Feng, W; Hu, S; Xu, F; Zhang, Y; Zheng, Z; Zhou, Z | 1 |
| Cho, YR; Choi, SY; Kim, MH; Min Lee, K; Park, TH; Sung Park, J; Yun, SC | 1 |
| Body, R; Jarman, H; Morris, N; Moss, P; Reynard, C | 1 |
| Bastos Fernandez, G; Baz Alonso, JA; Calvo Iglesias, F; Cequier Fillat, A; Cruz Gonzalez, I; De Miguel Castro, A; Fernandez Barbeira, S; Iñiguez Romo, A; Jimenez Diaz, VA; Juan Salvadores, P; Molina Navarro, E; Moreno, R; Ocampo Miguez, J; Ortiz Saez, A; Paredes Galan, E; Raposeiras Roubin, S; Romaguera, R; Serra Peñaranda, A; Tello-Montoliu, A; Valdes Chavarri, M | 1 |
| Easton, JD; Kim, AS | 1 |
| Lewis, RJ; Saver, JL | 1 |
| Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Wang, Y | 2 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Röther, J; Wang, Y; Wong, KSL | 1 |
| Andersson, M; Bhatt, DL; Fox, K; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Mehta, SR; Ridderstråle, W; Simon, T; Steg, PG | 1 |
| Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Eikelboom, JW; Fan, Y; Li, C; Li, J; Mei, L; Niles, K; Wang, F; Xu, K; Yang, L; Zhang, J; Zhang, S; Zhu, H; Zou, F | 1 |
| Nagalla, S; Sarode, R | 1 |
| Geisler, T; Kristensen, SD; Storey, RF; Sumaya, W | 1 |
| Aminian, A; Benit, E; Bolognese, L; Bryniarski, K; Buszman, P; Dominici, M; Ferrario, M; Franzone, A; Garg, S; Hamm, C; Heg, D; Huber, K; Janssens, L; Juni, P; Leonardi, S; Liebetrau, C; McFadden, E; Naber, C; Petrov, I; Piccolo, R; Prokopczuk, J; Serruys, P; Slagboom, T; Steg, G; Tumscitz, C; Valgimigli, M; van Geuns, RJ; Vranckx, P; Vrolix, M; Windecker, S; Zurakowski, A | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I | 1 |
| Chaitongrat, S; Lertsuwunseri, V; Mahachai, V; Pittayanon, R; Piyachaturawat, P; Prueksapanich, P; Rerknimitr, R; Srimahachota, S | 1 |
| Altındağ, R; Altıntaş, B; Baysal, E; Bilge, Ö; Burak, C; Ede, H; Karahan, MZ; Öztürk, Ö; Tanboğa, İH; Yaylak, B | 1 |
| Batista, DV; Feitosa, MPM; Lima, EG; Linhares Filho, JPP; Lobo Filho, HG; Serrano Júnior, CV; Soffiatti, CD | 1 |
| Azzalini, L; Li, L; Li, Y; Mao, Q; Tian, J; Tong, W; Xie, L; Zhao, X; Zheng, W; Zhou, D | 1 |
| Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Blanco, PF; Boccuzzi, G; Cequier, A; Cerrato, E; Cortese, M; D Ascenzo, F; De Filippo, O; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Magnani, G; Manzano-Fernández, S; Montabone, A; Montefusco, A; Morbiducci, U; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I | 1 |
| Carriero, A; De Luca, G; Kedhi, E; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Tonon, F; Verdoia, M | 1 |
| Baber, U; Goel, R | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KL | 1 |
| Hu, L; Jiang, HY; Li, ZZ; Xue, J; Yue, YH; Zhang, XG; Zhu, XQ | 1 |
| Audrone, V; Jurgaityte, J; Kupstyte-Kristapone, N; Lesauskaite, V; Norvilaite, R; Skipskis, V; Stuoka, M; Tamakauskas, V; Tatarunas, V | 1 |
| Calabrò, P; Cesaro, A; Cirillo, PL; Concilio, C; Crisci, M; Di Maio, D; Di Maio, M; Diana, V; Fimiani, F; Gragnano, F; Moscarella, E; Pariggiano, I; Taglialatela, V | 1 |
| Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J | 1 |
| Gurbel, PA; Navarese, EP; Tantry, US | 1 |
| Attmann, T; Boening, A; Conradi, L; Cremer, J; Danner, BC; de Waha, A; Fach, A; Grieshaber, P; Grothusen, C; Grubitzsch, H; Gusmini, F; Hambrecht, R; Hamm, C; Joost, A; Kastrati, A; Knosalla, C; Kuna, C; Lange, R; Lanig, C; Laufer, G; Meyer, A; Misfeld, M; Oberhoffer, M; Pader, P; Radke, PW; Sandner, SE; Schaefer, A; Schmoeckel, M; Schulz, R; Schunkert, H; Siepe, M; von Scheidt, M; Walther, T; Wimmer-Greinecker, G; Zeymer, U; Ziegelhöffer, T | 1 |
| Benedetto, U; Doble, B; Harris, J; Johnson, TW; Lasserson, D; Loke, Y; Mumford, A; Pithara, C; Pufulete, M; Redwood, S; Reeves, BC; Rogers, CA; Sterne, JAC; Wordsworth, S | 1 |
| Andric, T; Haller, PM; Huber, K; Jäger, B; Kahl, BS; Piackova, E; Stojkovic, S; Vargas, KG; Wojta, J | 1 |
| Carriero, A; De Luca, G; Kedhi, E; Marcolongo, M; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Blanco, NA; Carreño, NI; Frederick, GA; Galvis, V; Sánchez, WA; Tello, A | 1 |
| Jüni, P; Serruys, P; Valgimgli, M; Vranckx, P; Windecker, S | 1 |
| Martí, D; Sanmartín, M | 1 |
| Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F | 1 |
| Araszkiewicz, A; Grygier, M; Iwańczyk, S; Lesiak, M; Sikora, T; Skorupski, W | 1 |
| Al Sultan, AA; Almekhlafi, MA; Assis, Z; Goyal, M; Kashani, N; Podlasek, A | 1 |
| Wang, TKM; Wei, D | 1 |
| Farrokh, S; Hui, F; Lara, LR; Nault, K; Owusu, K; Spoelhof, B | 1 |
| Andric, T; Haller, PM; Huber, K; Jäger, B; Piackova, E; Spittler, A; Stojkovic, S; Wisgrill, L; Wojta, J | 1 |
| Benit, E; Bolognese, L; Buszman, P; Chang, CC; Chichareon, P; Colombo, A; de Winter, RJ; Dominici, M; Ferrario, M; Hamm, C; Jüni, P; Kogame, N; Komiyama, H; Modolo, R; Onuma, Y; Serruys, PW; Soliman, O; Steg, PG; Stoll, HP; Takahashi, K; Tomaniak, M; Tumscitz, C; Valgimigli, M; Vranckx, P; Windecker, S; Wykrzykowska, JJ | 1 |
| Grines, CL; Marshall, JJ | 1 |
| Eichinger, S; Kaider, A; Kollars, M; Kyrle, PA; Siller-Matula, JM; Traby, L; Wolkersdorfer, MF; Wolzt, M | 1 |
| Andersson, M; Bhatt, DL; Corbalán, R; Cornel, JH; Fox, K; Ge, J; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Leonsson-Zachrisson, M; Liu, Y; Mehta, SR; Nicolau, JC; Opolski, G; Ridderstråle, W; Simon, T; Steg, PG; Widimský, P; Zateyshchikov, D | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Cha, JY; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Džavík, V; Escaned, J; Gibson, CM; Gil, R; Gurbel, P; Hamm, CW; Han, YL; Henry, T; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, M; Kunadian, V; Marx, SO; Mehran, R; Mehta, SR; Moliterno, D; Ohman, EM; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Steg, PG; Weisz, G; Witzenbichler, B | 1 |
| Angiolillo, DJ; Bhatt, DL; Chang, CC; Chichareon, P; Dangas, GD; Deliargyris, EN; Hamm, C; Kogame, N; Modolo, R; Onuma, Y; Rademaker-Havinga, T; Serruys, PW; Steg, PG; Storey, RF; Takahashi, K; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S | 1 |
| Gimbel, ME; Kelder, JC; Nguyen, TA; Ten Berg, JM; Vos, GJA | 1 |
| Fernández-Ruiz, I | 1 |
| Carrie, D; Chang, CC; Chichareon, P; Chowdhary, S; de Winter, RJ; Eitel, I; Garg, S; Hamm, C; Kogame, N; Magro, M; Modolo, R; Ong, P; Onuma, Y; Ottesen, MM; Serruys, PW; Steg, PG; Stoll, HP; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S; Wykrzykowska, JJ; Zweiker, R | 1 |
| Collet, JP; Montalescot, G; Zeitouni, M | 1 |
| Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P | 1 |
| Bertrand, OF; Chang, CC; Chichareon, P; Ferreira, RC; Frey, B; Gori, T; Hamm, C; Hoole, SP; Jüni, P; Kogame, N; Koh, TH; Komiyama, H; Modolo, R; Moschovitis, A; Onuma, Y; Serruys, PW; Soliman, O; Sousa, A; Spitzer, E; Steg, PG; Takahashi, K; Tomaniak, M; Valgimigli, M; van Geuns, RJ; Vranckx, P; Windecker, S; Yap, SC; Zaman, A | 1 |
| Baber, U; Cao, D; Mehran, R | 1 |
| Barlis, P; Chang, CC; Chichareon, P; Colombo, A; Garg, S; Hamm, C; Jüni, P; Kerkmeijer, L; Kogame, N; Komiyama, H; Maillard, L; Mehran, R; Moccetti, T; Modolo, R; Onuma, Y; Piek, JJ; Serruys, PW; Steg, PG; Takahashi, K; Talwar, S; Tomaniak, M; Valgimigli, M; Windecker, S; Wykrzykowska, J | 1 |
| Böning, A; Kastrati, A; Laufer, G; Misfeld, M; Nowak, B; Sandner, SE; Schunkert, H; Stritzke, J; Tebbe, U; von Scheidt, M; Wiedemann, D | 1 |
| De Luca, G; Marcolongo, M; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Tonon, F; Verdoia, M | 1 |
| Alexopoulos, D; Ariza-Solé, A; Assi, EA; Autelli, M; Bernardi, A; Bianco, M; Blanco, PF; Boccuzzi, G; Cequier, A; Cerrato, E; D'ascenzo, F; Destefanis, P; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Gallo, D; Garay, A; Gili, S; Giustetto, C; Gravinese, C; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lopez-Cuenca, Á; Luciano, A; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Peyracchia, M; Pousa, IM; Pozzi, R; Quadri, G; Queija, BC; Raposeiras Roubin, S; Rinaldi, M; Rognoni, A; Rossini, R; Srdanovic, I; Taha, S; Templin, C; Valgimigli, M; Varbella, F; Velicki, L; Xanthopoulou, I | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Jansky, P; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Seung, KB; Steg, PG; Ten Berg, JM; Zateyshchikov, DA | 1 |
| Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Brunetti, ND; Caldarola, P; De Gennaro, L; Di Biase, M | 1 |
| Birnbaum, Y; Chen, H; Nylander, S; Sampaio, LC; Tran, D; Ye, Y | 1 |
| Liao, YWB; Wang, TKM | 1 |
| Gupta, A; Holm, M; Söderberg, M | 1 |
| Anderson, R; Baber, U; Buszman, PE; Chang, CC; Chichareon, P; Dominici, M; Geisler, T; Hamm, C; Jüni, P; Kogame, N; Modolo, R; Onuma, Y; Prokopczuk, J; Rademaker-Havinga, T; Sabaté, M; Serruys, PW; Spitzer, E; Steg, PG; Steinwender, C; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; Valkov, V; van Geuns, RM; Vranckx, P; Windecker, S; Zmudka, K | 1 |
| Anderson, R; Chang, CC; Chichareon, P; Chowdhary, S; Fath-Ordoubadi, F; Galasko, G; Garg, S; Hamm, CW; Hoole, S; Jüni, P; Kogame, N; Kukreja, N; Modolo, R; Oldroyd, KG; Onuma, Y; Serruys, PW; Stables, RH; Steg, PG; Takahashi, K; Tomaniak, M; Valgimigli, M; Windecker, S; Zaman, A | 1 |
| Daeter, EJ; Deneer, VHM; Hackeng, CM; Janssen, PWA; Kelder, JC; Klein, P; Soliman-Hamad, MA; Sonker, U; Ten Berg, JM; Tijssen, JGP; van Straten, AHM; Willemsen, LM | 1 |
| Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Gao, L; Geng, L; Guo, W; Li, H; Li, J; Wan, Q; Wang, X; Wang, Y; You, J; Zhang, Q | 1 |
| Raco, DL | 1 |
| Beitelshees, AL; Cavallari, LH; Diaby, V; Dillon, C; Duarte, JD; Empey, PE; Garbett, S; Gong, Y; Graves, J; Hillegass, WB; Holmes, AM; Johnson, JA; Lee, CR; Limdi, NA; Peterson, JF; Pisu, M; Skaar, TC; Zhou, Z | 1 |
| Angiolillo, DJ; Baber, U; Badimon, JJ; Dangas, G; Escolar, G; Farhan, S; Fuster, V; Gibson, CM; Gurbel, P; Joyce, L; Kini, AS; Mehran, R; Sartori, S; Sharma, SK; Vogel, B; Zafar, MU | 1 |
| Becker, RC; Sadayappan, S | 1 |
| Aung, K; Htay, T | 1 |
| Antman, EM; Huang, S; Neely, M; Ohman, EM; Roe, MT; Sun, MT; Wallentin, L; Wiviott, SD; Wong, CX | 1 |
| Álvarez-Antón, S; Carballeira, D; Concepción, R; Dejuán-Bitriá, C; Del Castillo, H; Delgado-Calva, FA; López-Soberón, E; Marschall, A; Martí, D; Morales, MJ; Palazuelos, J; Pérez-Guzmán, J | 1 |
| Finniss, M; Helton, T; Khalid, M; Khan, AA; Murtaza, G | 1 |
| Ajjan, RA; Naseem, KM; Sagar, RC | 1 |
| Tang, C; Xu, B; Yang, X; Yang, Y; Ye, C; Yu, L; Zhao, Q; Zhong, J; Zhu, Y | 1 |
| Auer, J; Lamm, G | 1 |
| Rey, F; Tanguay, JF | 1 |
| Baber, U; Dangas, G; Mehran, R | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Chandiramani, R; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Huber, K; Kaul, U; Kornowski, R; Kunadian, V; Mehran, R; Mehta, SR; Oldroyd, KG; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, RA; Weisz, G; Witzenbichler, B; Ya-Ling, H | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Chandiramani, R; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Giustino, G; Huber, K; Kaul, U; Kornowski, R; Kunadian, V; Mehran, R; Mehta, S; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Witzenbichler, B; Ya-Ling, H | 1 |
| Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM | 1 |
| Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS | 1 |
| Baldetti, L; Beneduce, A; Calvo, F; Capodanno, D; Cappelletti, AM; D'Ascenzo, F; De Ferrari, GM; Gallone, G; Godino, C; Gramegna, M; Melillo, F; Moroni, F; Pagnesi, M; Venuti, A | 1 |
| Akşit, E; Büyük, B; Çokkalender, Ö; Kurt, T | 1 |
| Hu, J; Liu, H; Wang, R; Wang, X; Xue, Q; Zhang, M; Zhao, Q; Zhu, J; Zhu, Y | 1 |
| Bhatt, DL; Bonaca, MP; Cohen, M; Gencer, B; Gurmu, Y; Hazen, SL; Johanson, P; Li, XS; Morrow, DA; Sabatine, MS; Steg, PG; Storey, RF; Wang, Z | 1 |
| Cannata, F; Cao, D; Chiarito, M; Condorelli, G; De Caterina, R; Ferrante, G; Godino, C; Panico, C; Regazzoli, D; Reimers, B; Sanz-Sánchez, J; Stefanini, GG; Sturla, M | 1 |
| Chichareon, P; Onuma, Y; Serruys, PW; Takahashi, K | 1 |
| Aylward, P; Bhatt, DL; Bonaca, MP; Dellborg, M; Furtado, RHM; Goto, S; Gurmu, Y; Isaza, D; Johanson, P; Kamensky, G; Magnani, G; Nicolau, JC; Steg, PG; Storey, RF; Venkateswaran, RV | 1 |
| De Luca, G; Khedi, E; Suryapranata, H; Verdoia, M | 1 |
| Branca, M; Franzone, A; Hamm, C; Heg, D; Jüni, P; Leonardi, S; McFadden, EP; Piccolo, R; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Windecker, S | 1 |
| Curtis, BR; Erdil, RM; Gilyard, SN; Knelson, EH; Leaf, RK; Malhotra, R; Puram, RV; Ranganathan, R; Van Beuningen, AM; Wallwork, R; Weber, BN | 1 |
| Chen, LL; Lu, WL; Tang, DD; Wang, JP; Wang, W; Yan, SR; Zhao, LH | 1 |
| Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP | 1 |
| Cimino, S; Cirillo, P; Coscioni, E; Esposito, G; Ferrone, M; Gargiulo, G; Giugliano, G; Ilardi, F; Morisco, C; Paolillo, R; Perrino, C; Schiattarella, GG; Stabile, E; Verde, N | 1 |
| Li, D; Li, X; Shen, S; Wu, H; Xiang, X | 1 |
| Guo, L; Huang, Q; Shi, X; Wang, G; Yang, Y; Yuan, D; Yuan, Y; Zhang, H; Zhao, Y | 1 |
| Murphy, SA; O'Donoghue, ML; Sabatine, MS | 1 |
| Badimon, J; Santos-Gallego, CG | 1 |
| Choi, YH; Deppe, AC; Gerfer, S; Liakopoulos, O; Schlachtenberger, G; Wahlers, TCW; Zeriouh, M | 1 |
| Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H | 1 |
| Shi, L; Wu, B | 1 |
| Esposito, G; Piccolo, R | 1 |
| Angiolillo, DJ; Calderone, D; Capodanno, D | 1 |
| Albers, GW; Amarenco, P; Bath, PM; Denison, H; Easton, JD; Evans, SR; Johnston, SC; Jonasson, J; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KL | 1 |
| De Luca, G; Gioscia, R; Kedhi, E; Marcolongo, M; Nardin, M; Negro, F; Suryapranata, H; Verdoia, M | 1 |
| Angioi, M; Barbato, E; Chichareon, P; Fontos, G; Gao, C; Hamm, C; Hara, H; Jüni, P; Kawashima, H; Kogame, N; Leandro, S; Modolo, R; Niethammer, M; Ono, M; Onuma, Y; Ribeiro, VG; Serruys, PW; Sharif, F; Steg, PG; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; van Klaveren, D; Verbeeck, J; Wang, R; Windecker, S | 1 |
| Bärnthaler, T; Buschmann, E; Heinemann, A; Mahla, E; Prüller, F; Schuligoi, R; Toth, GG | 1 |
| Jhaj, R; Khandelwal, G; Najmi, A; Ray, A; Sadasivam, B | 1 |
| Ballerini, P; Bruno, A; Contursi, A; Dovizio, M; Fullone, R; Marschler, S; Patrignani, P; Pizzicoli, G; Tacconelli, S; Zucchelli, M | 1 |
| Bérubé, S; Couture, ÉL; d'Entremont, MA; Desgagnés, N; Huynh, T; Karzon, A; Laferrière, C; Lepage, S; Nguyen, M; Verreault-Julien, L | 1 |
| Bekker, MWA; Beukema, KF; Brouwer, MA; Chan Pin Yin, DRPP; Daeter, EJ; Deneer, VHM; Gimbel, ME; Hackeng, CM; Janssen, PWA; Kelder, JC; Klein, P; Peper, J; Rensing, BJWM; Soliman-Hamad, MA; Sonker, U; Swaans, MJ; Ten Berg, JM; Tijssen, JGP; van der Harst, P; van Es, HW; van Straten, AHM; Vlot, EA; von Birgelen, C; Willemsen, LM | 1 |
| Goldman, S | 1 |
| Dobesh, PP; Finks, SW; Trujillo, TC | 1 |
| Choudhary, R; Deora, S | 1 |
| Angiolillo, DJ; Baber, U; Dangas, GD; Mehran, R | 1 |
| Asad, ZUA; Baber, U | 1 |
| Chichareon, P; de Silva, R; Gao, C; Hamm, C; Hara, H; Huber, K; Jasionowicz, P; Jüni, P; Kawashima, H; Khamis, R; Koenig, W; Ono, M; Onuma, Y; Piek, JJ; Serruys, PW; Steg, PG; Storey, RF; Tomaniak, M; Vrolix, M; Wang, R; Windecker, S; Wykrzykowska, JJ | 1 |
| Bath, PM; Xiong, Y | 1 |
| Carrie, D; Cotton, J; de Winter, RJ; Gao, C; Garg, S; Hamm, C; Hara, H; Jüni, P; Kawashima, H; Leibundgut, G; Ono, M; Onuma, Y; Sabate, M; Serruys, PW; Sharif, F; Steg, PG; Steinwender, C; Suryapranata, H; Takahashi, K; Thury, A; Tomaniak, M; Valgimigli, M; Vranckx, P; Walsh, S; Wang, R; Windecker, S; Wykrzykowska, J | 1 |
| Bavishi, C | 1 |
| Choudhary, R; Deora, S; Kaushik, A | 1 |
| Amarenco, P; Johnston, SC | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Cha, JY; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Džavik, V; Escaned, J; Gibson, CM; Gil, R; Gurbel, P; Hamm, CW; Han, YL; Henry, T; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, M; Kunadian, V; Marx, SO; Mehran, R; Mehta, S; Moliterno, D; Nicolas, J; Ohman, EM; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Steg, PG; Weisz, G; Witzenbichler, B | 1 |
| Storey, RF | 1 |
| Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC | 1 |
| Friede, KA; Ginsburg, GS; Infeld, M; Knickerbocker, HJ; Ortel, TL; San, TR; Voora, D | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Aungraheeta, R; Baos, S; Baumbach, A; Bowles, R; Collett, L; Hutchinson, JL; Johnson, TW; Molina, M; Mumford, AD; Mundell, SJ; Nkau, M; Reeves, BC; Reilly-Stitt, C; Rogers, CA | 1 |
| Hill, MD | 1 |
| Baek, JW; Heo, YJ; Jeong, HW; Jin, SC; Kim, HJ; Kim, JS; Kim, SB; Kim, SH; Kim, ST; Lee, H; Park, JH | 1 |
| Adamson, C; Anderson, L; Campbell, M; Good, R; Hennigan, BW; Martin, L; Oldroyd, KG; Parker, WAE; Serruys, PW; Storey, RF | 1 |
| Amoroso, G; de Winter, RJ; Fagel, ND; Herrman, JP; Oosterwerff, EFJ; Patterson, MS; Riezebos, RK; Slagboom, T; Tijssen, JGP; van der Schaaf, RJ; Verheugt, FWA; Vink, MA; Vos, NS | 1 |
| Corbett, SJ; Ftouh, S; Lewis, S; Lovibond, K | 1 |
| Chen, Y; Wang, B; Wang, W; Wei, S | 1 |
| Chen, WT; Chien, LN; Hsieh, YC; Hsu, CY; Huang, CY; Yeh, JS | 1 |
| Lunardi, M; Onuma, Y; Serruys, PW | 1 |
| Ahmed, A; Cheng, T; Harky, A; Ravindran, W; Sembi, N; Ulucay, E | 1 |
| Fang, W; Gou, X; Hou, K; Li, F; Li, Y; Lv, N; Xu, D | 1 |
| Angiolillo, DJ; Ardissino, D; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Goudev, A; Im, K; Johanson, P; Kamensky, G; López-Sendón, J; Magnani, G; Oude Ophius, T; Parkhomenko, A; Sabatine, MS; Steg, PG; Storey, RF | 1 |
| Cassese, S; Holdenrieder, S; Kastrati, A; Ndrepepa, G | 1 |
| Shrikant Kulkarni, N | 1 |
| Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, HM; Lee, SJ; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH | 1 |
| Beasley, M; Brown, TM; Cai, A; Clarkson, SA; Dillon, C; Heindl, B; Limdi, N | 1 |
| Boasi, V; Cannarile, P; Cattunar, S; Gomez, L; Mascelli, G; Perri, D; Pingelli, N; Sanchez, F; Tacchi, C; Vercellino, M | 1 |
| Cho, JY; Lee, SY; Oh, SK; Yun, KH | 1 |
| Dong, Z; Pan, L; Zhai, H; Zhang, B | 1 |
| Böning, A; Kastrati, A; Laufer, G; Milojevic, M; Sandner, SE; Schunkert, H; von Scheidt, M; Wiedemann, D; Zellmer, S; Zimpfer, D | 1 |
| Jneid, H; Kamran, H; Kayani, WT; Khalid, U; Levine, GN; Nambi, V; Virani, SS | 1 |
| Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G | 1 |
| Carretero Rodrigo, M; Lipperheide Vallhonrat, I; Ortega Marcos, J; Parra Esteban, C; Silva Melchor, L; Vela Martín, P | 1 |
| Amerena, J; Bhatt, DL; Bueno, H; Dalby, AJ; Fox, K; Himmelmann, A; Kiss, RG; Kosiborod, MN; Lee, JJ; Leiter, LA; Lev, EI; Liu, Y; McGuire, DK; Mehta, SR; Prats, J; Ridderstråle, W; Simon, T; Steg, PG; Teoh, H | 1 |
| Dillinger, JG; Henry, P | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Farhan, S; Gibson, CM; Gil, R; Goel, R; Han, YL; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, SR; Moliterno, D; Ohman, EM; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Vogel, B; Witzenbichler, B; Zhang, Z | 1 |
| Bae, JW; Cho, DK; Choi, SH; Gwon, HC; Hahn, JY; Jeong, JO; Oh, JH; Park, YH; Rha, SW; Song, PS; Song, YB | 1 |
| Amir, O; Arazi, M; Carasso, S; Diab, S; Grosman-Rimon, L; Kachel, E; Raanani, E; Shalabi, A; Sternik, L | 1 |
| Adamski, P; Badarienė, J; Barańska, M; Bartuś, S; Budaj, A; Dobrzycki, S; Fidor, Ł; Gąsior, M; Gessek, J; Gierlotka, M; Gil, R; Gorący, J; Gorog, DA; Grzelakowski, P; Hajdukiewicz, T; Jaguszewski, M; Janion, M; Kasprzak, J; Kern, A; Klecha, A; Kleinrok, A; Kochman, W; Krakowiak, B; Kubica, A; Kubica, J; Legutko, J; Lesiak, M; Navarese, EP; Niezgoda, P; Nosal, M; Ostrowska, M; Pietrzykowski, Ł; Piotrowski, G; Podhajski, P; Przybylski, A; Roleder, T; Siller-Matula, JM; Skonieczny, G; Sobieszek, G; Specchia, G; Tycińska, A; Umińska, JM; Wojakowski, W; Wojciechowski, D; Wójcik, J; Zielińska, M; Żurakowski, A | 1 |
| Bastos-Fernandez, G; Baz-Alonso, JA; Cruz-González, I; De Miguel-Castro, A; Fernández-Barbeira, S; Figueiras-Guzman, A; Iñiguez-Romo, A; Jimenez-Diaz, VA; Molina-Navarro, E; Moreno, R; Ortiz-Saez, A; Paredes-Galán, E; Romaguera, R; Salvadores, PJ; Tello-Montoliu, A; Trejo-Velasco, B | 1 |
| Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D | 1 |
| Case, BC; Doros, G; Medranda, GA; Waksman, R; Weintraub, WS; Yerasi, C; Zhang, C | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Ohman, EM; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z | 1 |
| Aznaouridis, K; Bei, E; Iakovou, I; Kalantzis, C; Kalogeras, K; Katsianos, E; Kosmas, E; Leucker, TM; Moldovan, CM; Oikonomou, E; Papaioannou, TG; Siasos, G; Stasinopoulou, M; Tountopoulou, A; Tousoulis, D; Toutouzas, K; Vavuranakis, M; Vavuranakis, MA; Voudris, V; Vrachatis, D | 1 |
| Amarenco, P; Birve, F; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y | 1 |
| Parker, WAE; Sanderson, NC; Storey, RF | 1 |
| Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ | 1 |
| Ariza-Solé, A; Bonaca, M; Giannitsis, E; Hedberg, J; Hewitt, C; Jernberg, T; Lambrelli, D; Lesén, E; Maggioni, AP; Simeone, JC; Storey, RF; Ten Berg, J | 1 |
| Huang, WY; Lee, M; Ovbiagele, B | 1 |
| Björklund, E; Hansson, EC; Jeppsson, A; Malm, CJ; Martinsson, A; Nielsen, SJ; Omerovic, E; Pivodic, A; Romlin, BS; Tygesen, H | 1 |
| Amarenco, P; Aunes, M; Denison, H; Evans, SR; Himmelmann, A; Jahreskog, M; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Nylander, S; Röther, J; Wang, Y | 1 |
| Benit, E; Diletti, R; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; Mc Fadden, EP; Odutayo, A; Onuma, Y; Räber, L; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Windecker, S | 1 |
| Cassese, S; Holdenrieder, S; Joner, M; Kastrati, A; Kessler, T; Kufner, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Schunkert, H; Wiebe, J; Xhepa, E | 1 |
| Serebruany, V; Tanguay, JF | 1 |
| Adamski, P; Alexopoulos, D; Badarienė, J; Budaj, A; Buszko, K; Dąbrowski, P; Di Somma, S; Dudek, D; Gąsior, M; Giannitsis, E; Gil, R; Gorog, DA; Gruchała, M; Gurbel, PA; Horszczaruk, G; Jaguszewski, MJ; James, S; Jeong, YH; Jilma, B; Kasprzak, J; Kleinrok, A; Kryjak, M; Kubica, A; Kubica, J; Legutko, J; Lesiak, M; Navarese, EP; Niezgoda, P; Ostrowska, M; Patti, G; Romanek, J; Siller-Matula, JM; Specchia, G; Tantry, U; Tycińska, A; Wojakowski, W | 1 |
| Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD | 1 |
| Lyu, SQ; Shao, XH; Wang, J; Wu, S; Yang, YM; Zhang, H; Zhu, J | 1 |
| Jim, J; Liang, P; Marcaccio, CL; Patel, PB; Rastogi, V; Schermerhorn, ML; Schneider, PA; Stangenberg, L | 1 |
| Bath, PM; Chang, L; Dong, Q; Feng, Y; Jiang, Y; Jing, J; Johnston, SC; Li, G; Li, H; Li, W; Li, Z; Lin, J; Liu, L; Man, H; Meng, X; Niu, S; Pan, Y; Wang, A; Wang, B; Wang, L; Wang, Y; Xie, X; Xu, A; Xu, J; Zhao, J; Zhao, X; Zhuang, X | 1 |
| Cutlip, DE; Deliargyris, EN; Doros, G; Gibson, CM; Kroger, H; Lee, VT; Mack, MJ; Ohman, EM; Schneider, DJ; Sellke, FW; Thourani, VH | 1 |
| Chen, CC; Chen, CT; Chien, SC; Hsieh, PC; Liu, YT; Liu, ZH; Wang, AY; Wang, YC; Yeap, MC | 1 |
| Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Zitikyte, G | 1 |
| Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BG; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Shin, DH | 1 |
| Huber, K; Mehran, R; Vogel, B | 1 |
| Ferro, A; Passacquale, G; Perera, D; Sharma, P | 1 |
| Alkhalil, M; Bell, A; Cantor, WJ; Goodman, SG; Kuzemczak, M; Stern, S; Welsford, M | 1 |
| Alam, M; Atar, D; Birnbaum, Y; Davidson, SM; Jneid, H; Kitakaze, M; Uretsky, BF; Ye, R; Yellon, DM | 1 |
| Li, F; Peng, R | 1 |
| Akin, I; Bernlochner, I; Cassese, S; Gewalt, S; Hemetsberger, R; Ibrahim, T; Joner, M; Kastrati, A; Kufner, S; Lahu, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Sager, HB; Schunkert, H; Schüpke, S; Valina, C; Witzenbichler, B; Wöhrle, J; Xhepa, E | 1 |
| Friebel, J; Hassanein, A; Jakobs, K; Landmesser, U; Puccini, M; Rauch, C; Rauch, U | 1 |
| Arrivi, A; Benit, E; Calabrò, P; Chichareon, P; Gargiulo, G; Gragnano, F; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; Leonardi, S; McFadden, EP; Möllmann, H; Onuma, Y; Schmidlin, K; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; Van Geuns, RJ; Vranckx, P; Windecker, S; Zurakowski, A; Zwahlen, M | 1 |
| Gao, C; Garg, S; Hamm, C; Hara, H; Kawashima, H; Ono, M; Onuma, Y; Piek, JJ; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Wang, R; Windecker, S; Wykrzykowska, JJ | 1 |
| Dietze-Torres, J; Gerdes, C; Glunz, J; Heitmeier, S; Laux, V; Roehrig, S; Stampfuss, J; Tersteegen, A; Visser, M | 1 |
| Angiolillo, DJ; Baber, U; Bian, L; Chen, J; Chen, SL; Cheng, X; Chunguang, Q; Claessen, BE; Cohen, DJ; Dangas, G; Gibson, CM; Goel, R; Hailong, L; Han, Y; Kastrati, A; Krucoff, M; Li, Y; Liu, Y; Luo, S; Mehran, R; Mehta, SR; Ohman, EM; Qiang, W; Sartori, S; Sharma, S; Steg, PG; Su, X; Sun, Y; Tao, J; Wang, G; Wang, J; Xu, Y; Zhang, R; Zhang, Z; Zhao, X; Zhou, Y; Zhu, J | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z | 1 |
| Alraies, MC; Cuisset, T; Faisaluddin, M; Fischman, DL; Khalil, F; Pasha, AK; Rao, SV; Sabouret, P; Sandhyavenu, H; Savage, MP; Ullah, W; Zahid, S | 1 |
| Bellesini, M; Galli, E; Maroni, L; Pomero, F; Squizzato, A | 1 |
| Angelini, F; Baldetti, L; Bocchino, PP; Chieffo, A; Conrotto, F; D'Ascenzo, F; de Ferrari, GM; DE Filippo, O; DE Lio, G; Melillo, F; Montefusco, A; Omedè, P; Piroli, F; Saglietto, A | 1 |
| Angiolillo, DJ; Bass, TA; Been, L; Franchi, F; Galli, M; Geisler, T; Jaoude, PA; Jennings, LK; Jia, S; Lee, CH; Maaliki, N; Pineda, AM; Rivas, A; Rollini, F; Soffer, D; Suryadevara, S; Zenni, MM; Zhou, X | 1 |
| Li, X; Lv, Q; Wang, Z; Xia, L; Yao, Y; Ye, Y; Zou, Y | 1 |
| Han, X; He, M; Kong, Y; Li, Y; Liu, G; Ren, J; Shi, J; Yan, W; Zhang, Y; Zhao, Z | 1 |
| Chan, YH; Ganguly, A; Hwa, K; Li, Z; Ling, XB; Su, KJ; Tam, CF; Tse, HF; Wong, YK; Zhu, X | 1 |
| Liu, S; Shah, J; Yu, W | 1 |
| An, HJ; He, YY; Li, S; Sheng, XY; Ye, YF; Zhao, JL | 1 |
| Chen, B; Lin, Y; Xiang, F | 1 |
| Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y | 1 |
| Appel, KF; Degenhardt, R; Ghanem, A; Jörnten-Karlsson, M; Karlson, BW; Knutsson, M; Köhler, T; Krackhardt, F; Maier, LS; Niklasson, A; Ohlow, MA; Theres, H; Tschöpe, C; Vom Dahl, J; Waliszewski, M | 1 |
| Esposito, G; Gargiulo, G; Serino, F | 1 |
| Campo, G; Pavasini, R | 1 |
| Battinelli, EM; Guo, Q; Italiano, JE; Malloy, MW; McAllister, SS; Roweth, HG | 1 |
| Andersson, M; Bhatt, DL; Bueno, H; Darlington, O; De Luca, L; Fox, KM; Harrington, RA; Himmelmann, A; Hoskin, L; James, SK; Leiter, LA; McEwan, P; Mehta, SR; Mellström, C; Ridderstråle, W; Simon, T; Steg, PG; Tank, A | 1 |
| Benit, E; Bhatt, DL; Buszman, P; Deliargyris, EN; Dominici, M; Ferrario, M; Gao, C; Garg, S; Hamm, C; Hara, H; Huber, K; Janssens, L; Jüni, P; Kawashima, H; O'Leary, N; Ono, M; Onuma, Y; Piek, JJ; Serruys, PW; Storey, RF; Valgimigli, M; Vranckx, P; Wang, R; Windecker, S; Wykrzykowska, JJ; Żurakowski, A | 1 |
| Anderson, M; Chuck, C; Feler, J; Jayaraman, MV; McTaggart, R; Moldovan, K; Poggi, J; Sweeney, J; Torabi, R | 1 |
| Chen, C; Chen, Z; Gu, X; Liu, W; Mao, X; Ren, S; Tao, L; Zhang, L; Zhao, Y | 1 |
| Friede, KA; Gales, J; Ginsburg, GS; Kraus, WE; Myers, RA; Ortel, TL; Shah, SH; Voora, D; Zhbannikov, I | 1 |
| Amos, D; Brieger, D; Chew, DP; Hou, M; Hyun, K; Kritharides, L | 1 |
| Andreadou, I; Heusch, G; Kleinbongard, P; Lieder, HR; Schrör, K; Tsoumani, M | 1 |
| Hu, F; Qi, G; Wang, P; Xing, Y; Yang, J; Zhang, X | 1 |
| Bath, PM; Chen, G; Huang, P; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, F; Wang, Y; Xie, X; Zhao, X; Zuo, Y | 1 |
| Costa, TGR; Franken, M; Guerra, JCC; Katz, M; Lemos Neto, PA; Pesaro, AEP | 1 |
| Bath, PM; Cheng, J; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, Y; Wang, Z; Xie, X; Yang, H; Zhao, X | 1 |
| Demchuk, AM; Jahn, B; Menon, BK; Micieli, A; Siebert, U; Singh, N | 1 |
| Alenazy, FO; Harbi, MH; Nicolson, PLR; Smith, CW; Thomas, MR; Tiwari, A; Watson, SP | 1 |
| Aboalhasan, E; Abu-Dogosh, A; Abu-Salman, A; Alnsasra, H; Arbel, R; Azuri, J; Barrett, O; El Nasasra, A; Golan, YB; Hammerman, A; Tsaban, G; Weissberg, I; Westreich, R | 1 |
| Chen, W; Guo, L; Jiang, L; Liu, L; Pan, Y; Wang, Y; Xu, Y; Yao, D; Zhao, X | 1 |
| Angiolillo, DJ; Audisio, K; Fremes, SE; Gaudino, M; Janssen, PWA; Kulik, A; Mehran, R; Peper, J; Redfors, B; Ruel, M; Sandner, S; Saw, J; Soletti, GJ; Starovoytov, A; Ten Berg, JM; Willemsen, LM; Zhao, Q; Zhu, Y | 1 |
| Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C | 1 |
| Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC | 1 |
| Angiolillo, DJ; Baber, U; Beerkens, FJ; Briguori, C; Cao, D; Claessen, B; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Gil, R; Huber, K; Kastrati, A; Kornowski, R; Krucoff, MW; Kunadian, V; Marx, S; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Steg, PG; Weisz, G; Zhang, Z | 1 |
| Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B | 1 |
| de Borst, GJ; Hannink, G; Kramers, K; Maas, DPMSM; Mees, BME; Reijnen, MMPJ; Riksen, NP; Ten Cate, H; van der Vijver-Coppen, RJ; Warlé, MC; Willems, LH; Zeebregts, CJ | 1 |
| Alexander, JH; Bhatt, DL; Budaj, A; Campo, G; Coppolecchia, R; Eikelboom, J; Ferreiro, JL; Hermanides, RS; James, SK; Jones, WS; Keller, L; Kirsch, B; Merkely, B; Mundl, H; Rao, SV; Shibasaki, T | 1 |
| Calderone, D; Capodanno, D; Scalia, L | 1 |
| Angiolillo, DJ; Been, L; Franchi, F; Galli, M; Rollini, F; Zenni, MM | 1 |
| Grotta, JC; Pîrlog, BO | 1 |
| Li, X; Lv, Q; Wang, Z; Xia, L; Xu, Q; Yao, Y; Ye, Y; Zou, Y | 1 |
| Moustafa, B; Testai, FD | 1 |
| Kanny, O; Khan, H; Qadura, M; Syed, MH | 1 |
| Abtan, J; Bhatt, DL; Bueno, H; Ducrocq, G; Eagle, KA; Elbez, Y; Fox, K; Goto, S; Harrington, RA; Leiter, LA; Lev, E; Mehta, SR; Ohman, EM; Pais, P; Petrov, I; Simon, T; Sinnaeve, PR; Smith, SC; Steg, PG; Wilson, P | 1 |
| Böning, A; Conradi, L; Danner, B; Färber, G; Kastrati, A; Manville, E; Niessner, A; Sandner, S; Schunkert, H; von Scheidt, M; Zeymer, U; Zimpfer, D | 1 |
| Abramowitz, J; Ben-Dor, I; Bernardo, NL; Case, BC; Deksissa, T; Hashim, H; Rogers, T; Satler, LF; Shea, C; Sutton, JA; Torguson, R; Waksman, R; Zhang, C | 1 |
| Kim, HH; Yoo, KJ; Youn, YN | 1 |
| Li, X; Lin, Y; Peng, W; Zhang, Y | 1 |
| Aref, HM; El-Khawas, H; Elbassiouny, A; Roushdy, TM; Shokri, HM; Zeinhom, MG | 1 |
| Behnoush, AH; Khalaji, A; Peiman, S | 1 |
| Sandner, S; Siller-Matula, JM | 1 |
| Bernardo, E; Fernández-Ortiz, A; Gómez-Polo, JC; Jiménez, JJ; Martín-Asenjo, R; Moreno, G; Ortega-Pozzi, MA; Pérez-Villacastín, J; Vilacosta, I; Vivas, D | 1 |
| Gaudino, M; Redfors, B; Sandner, S | 1 |
| Liang, CS; Tseng, PT; Zeng, BY | 1 |
| Bath, PM; Cao, M; Chen, W; Jiang, Y; Jing, J; Li, H; Li, J; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, F; Wang, Y; Xie, X; Xu, J; Zhao, X; Zuo, Y | 1 |
| Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X | 1 |
| Li, X; Lv, Q; Wang, Z; Xu, S; Yao, Y | 1 |
| Barreau, X; Berge, J; Cagnazzo, F; Collemiche, FL; Costalat, V; Dargazanli, C; Derraz, I; Ferreira, I; Gariel, F; Gascou, G; Lefevre, PH; Marnat, G; Papaxanthos, J; Radu, RA; Riquelme, C | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Han, YL; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Kunadian, V; Mehran, R; Mehta, SR; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, RA; Spirito, A; Vogel, B; Zhang, Z | 1 |
| Aldica, M; Anchidin, OI; Blendea, D; Moldovan, H; Molnar, A; Nemes, A; Pop, D; Rosianu, SH | 1 |
| Alfredsson, J; Erlinge, D; Gudbjartsson, T; Gunn, J; James, S; Jeppsson, A; Malm, CJ; Møller, CH; Nielsen, SJ; Sartipy, U; Tønnessen, T | 1 |
| Abhaichand, R; Agrawal, DK; Arambam, P; Bangalore, S; Banker, D; Chandra, S; Garg, R; Kaul, U; Khan, A; Koduganti, SC; Mody, R; Moorthy, N; Parida, AK; Reddy, KMK; Sarma, PR; Sharma, R; Sinha, SK | 1 |
| Jing, J; Li, H; Li, Z; Liu, H; Meng, X; Wang, A; Wang, Y; Xu, Q | 1 |
| Atar, D; Gurvich, ML; Marciniak, TA; Serebruany, VL; Tanguay, JF | 1 |
| Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J | 1 |
| Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S | 1 |
| Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, B; Lee, SJ; Lee, YJ | 1 |
| Chen, D; Gao, X; He, C; Huan, X; Huang, X; Li, Y; Liu, L; Zhang, T | 1 |
| Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P | 1 |
| He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L | 1 |
| De Caterina, R | 1 |
| Bai, J; Chen, Y; Dong, P; Gong, X; Hua, R; Ke, Y; Li, C; Liu, K; Wang, Q; Wang, X; Wu, T; Xiao, J; Ying, L; Zhang, B; Zhang, J; Zhang, W; Zhang, X; Zhu, L | 1 |
| Genç, S; Günalp Eneyli, M; Koca, A; Oğuz, AB; Polat, O; Yeter, AS | 1 |
| Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Xu, Q; Zhao, X | 1 |
| Guo, BY; Hao, J; Liu, JM; Ren, JL; Sun, YQ; Wang, CC; Yang, XL; Zhang, XR; Zhao, JJ; Zhao, Q | 1 |
| Andrade, PB; Angiolillo, DJ; Antunes, MO; Assis, SRL; Bacal, F; Bergo, RR; Berwanger, O; Costa, TAO; Dall'Orto, FTC; de Paula, JET; Franken, M; Furtado, RHM; Guimarães, PO; Hirai, JCS; Joaquim, RM; Lemos, PA; Lopes, RD; Mangione, FM; Mariani, J; Monfardini, F; Nascimento, BR; Nicolau, JC; Ohe, LN; Onuma, Y; Pitta, FG; Sampaio, FBA; Sarmento-Leite, R; Serpa, RG; Serruys, PW; Silveira, FS; Silveira, MS; Sposito, AC; Tavares, CAM; Valgimigli, M | 1 |
| An, L; Hau, WK; Lei, M; Li, Y; Nie, S; Wang, J; Wang, X; Xue, Z; Yang, Y; Zhao, Z; Zhou, H | 1 |
| Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X | 1 |
| Benedetto, U; Doble, B; Harris, J; Hopewell-Kelly, N; Johnson, T; Lasserson, D; Loke, Y; Mahadevan, K; Mumford, A; Pithara, C; Pouwels, KB; Pufulete, M; Redwood, S; Reeves, B; Rogers, C; Sterne, J; Wordsworth, S | 1 |
| Bertelli, A; Berteotti, M; Cesarini, D; Gori, AM; Marcucci, R; Muraca, I; Sorrentino, A; Valenti, R | 1 |
| Chen, F; Guo, YF; Tian, MY; Wang, XY | 1 |
| Alieva, AK; Antonova, OA; Dobrovolsky, AB; Khaspekova, SG; Mazurov, AV; Muravlev, IA; Pevzner, DV | 1 |
| Al-Roub, NM; Almarzooq, ZI; Kinlay, S | 1 |
| Alenazy, FO; Brady, P; Connolly, DL; Harbi, MH; Hargreaves, O; Harrison, P; Jandrot-Perrus, M; Kalia, N; Kavanagh, DP; Kirchhof, P; Mangin, PH; Nicolson, PLR; Price, J; Slater, A; Thomas, MR; Tiwari, A; Watson, SP | 1 |
| Bath, PM; Claiborne Johnston, S; Jiang, Y; Jing, J; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X | 1 |
| Ge, F; Li, M; Lin, H; Shi, J; Yang, Q; Zhang, X | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, D; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Gil, R; Han, YL; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Mendieta, G; Moliterno, DJ; Ohman, EM; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Spirito, A; Steg, PG; Vogel, B | 1 |
| Angiolillo, DJ; Cho, JY; Gorog, DA; Jang, Y; Jeong, YH; Kim, JW; Lee, SY; Yun, KH | 1 |
| Cai, Y; Chen, Z; He, Y; Li, C; Zhang, J | 1 |
| Chang, YM; Lee, TL; Sung, PS | 1 |
| Gao, ST; Ma, L; Wang, Y | 1 |
| Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Han, YL; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, M; Kunadian, V; Mehran, R; Mehta, SR; Moliterno, D; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, RA; Spirito, A; Steg, PG; Vogel, B | 1 |
| Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Ielasi, A; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Stefanini, GG; Steg, PG; Vogel, B; Weisz, G; Witzenbichler, B; Zhang, Z | 1 |
| Jovanovic, M; Sabovic, M | 1 |
| Bath, PM; Jia, W; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, C; Wang, Y; Xie, X; Xu, Q; Zhang, X; Zhao, X | 1 |
| Huang, HY; Katz, AJ; Lin, FJ; Lin, SY; Wang, CC; Wu, CH | 1 |
| Liu, C; Ma, L | 1 |
125 review(s) available for aspirin and ticagrelor
| Article | Year |
|---|---|
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2006 |
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Humans; Membrane Proteins; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2007 |
Clinical overview of promising nonthienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Ticagrelor | 2008 |
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2008 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom | 2010 |
New antithrombotic agents--insights from clinical trials.
Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
[Coronary heart disease - what is of importance after coronary intervention?].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Humans; Integrin alpha2; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Interactions; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Perioperative management of antiplatelet agents in patients undergoing cardiac surgery.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Ticlopidine | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
A critical overview on ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Double-Blind Method; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Novel agents for antithrombotic therapy in cardiology].
Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2012 |
Ticagrelor: the first novel reversible P2Y(12) inhibitor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2013 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions].
Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Cardiovascular pharmacology core reviews: aspirin.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Secondary Prevention; Ticagrelor | 2013 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases | 2014 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Ticagrelor | 2014 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thiophenes; Ticagrelor | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Spontaneous coronary artery dissection: the management dilemma continues.
Topics: Adenosine; Adult; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Carbazoles; Carvedilol; Coronary Angiography; Coronary Vessel Anomalies; Diagnosis, Differential; Echocardiography; Electrocardiography; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Propanolamines; Purinergic P2Y Receptor Antagonists; Ticagrelor; Vascular Diseases | 2015 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2015 |
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges.
Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopidogrel; Colonic Neoplasms; Drug Therapy, Combination; Female; Humans; Lactones; Male; Mice; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neoplastic Cells, Circulating; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Factors; Species Specificity; Ticagrelor; Ticlopidine; Time Factors | 2015 |
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Transcatheter Aortic Valve Replacement | 2016 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Drug Interactions; Esomeprazole; Gastrointestinal Hemorrhage; Gene Expression; Humans; Hydrogen-Ion Concentration; Peptic Ulcer; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2017 |
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; History, 20th Century; History, 21st Century; History, Ancient; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor; Ticlopidine | 2016 |
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Arylsulfonates; Aspirin; Clopidogrel; Disease Management; Humans; Nurse Practitioners; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2017 |
Antiplatelet treatments: recent evidence from randomized controlled trials.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Atherosclerosis; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2017 |
[Management of the bleeding risk associated with antiplatelet agents].
Topics: Adenosine; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
[Antiplatelet agents and transfusion].
Topics: Adenosine; Antidotes; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine | 2017 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Failure | 2017 |
A Primer on Bleeding Risk and Management Strategies of Newer Oral Anti Platelet Agents in Cardiovascular Disease.
Topics: Adenosine; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stents; Ticagrelor | 2018 |
Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; England; Humans; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Secondary Prevention; Technology Assessment, Biomedical; Thrombosis; Ticagrelor; Wales | 2018 |
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Humans; Observational Studies as Topic; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2018 |
Optimising antiplatelet utilisation in the acute care setting: a novel threshold for medical intervention in suspected acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Humans; London; Monte Carlo Method; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Time Factors | 2019 |
Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy.
Topics: Aspirin; Blood Loss, Surgical; Blood Platelets; Cyclooxygenase Inhibitors; Hemorrhage; Hemostasis; Humans; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thromboembolism; Ticagrelor | 2019 |
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Topics: Acute Coronary Syndrome; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Decision Making; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Rivaroxaban; Secondary Prevention; Stroke; Ticagrelor | 2019 |
Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin.
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2019 |
Massive Hyphaema Following Laser Iridotomy in a Patient on Dual Antiplatelet Therapy (Aspirin plus Ticagrelor): Case report and literature review.
Topics: Aspirin; Colombia; Glaucoma, Angle-Closure; Humans; Hyphema; Iridectomy; Laser Therapy; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Ticagrelor | 2019 |
Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Self Expandable Metallic Stents; Ticagrelor; Treatment Outcome | 2020 |
Neuro-Interventional Use of Oral Antiplatelets: A Survey of Neuro-Endovascular Centers in the United States and Review of the Literature.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome; United States | 2021 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin | 2020 |
Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor.
Topics: Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Dual Anti-Platelet Therapy; Eye Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2020 |
Antiplatelet therapies in diabetes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Primary Prevention; Secondary Prevention; Thrombosis; Ticagrelor | 2020 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor | 2020 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine | 2020 |
Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Ticagrelor; Time Factors; Treatment Outcome | 2021 |
Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Withholding Treatment | 2020 |
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Complications; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Ticagrelor | 2021 |
Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Thrombosis; Ticagrelor; Time Factors | 2020 |
The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Secondary Prevention; Ticagrelor | 2020 |
Antiplatelet Therapy for Transient Ischemic Attack and Minor Stroke.
Topics: Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Risk Assessment; Secondary Prevention; Severity of Illness Index; Ticagrelor | 2020 |
Anticoagulation and antiplatelet therapy post coronary artery bypass surgery.
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis.
Topics: Aspirin; Bayes Theorem; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Early Medical Intervention; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Mortality; Platelet Aggregation Inhibitors; Proportional Hazards Models; Secondary Prevention; Ticagrelor | 2021 |
Ticagrelor: clinical development and future potential.
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2021 |
Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study.
Topics: Aged; Aspirin; Humans; Medicare; Myocardial Infarction; Observational Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome; United States | 2021 |
P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis.
Topics: Aspirin; Cerebral Infarction; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor | 2022 |
Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Ischemic Attack, Transient; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Ticagrelor | 2022 |
Antiplatelet therapy in cardiovascular disease: Current status and future directions.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2022 |
A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Drug Therapy, Combination; Europe; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor | 2022 |
Do We Really Need Aspirin Loading for STEMI?
Topics: Animals; Aspirin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Morphine Derivatives; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Quality of Life; Secondary Prevention; Stroke; Ticagrelor | 2022 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Ticagrelor | 2023 |
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2022 |
High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Dyspnea; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Saphenous Vein; Ticagrelor; Treatment Outcome; Vascular Diseases | 2023 |
Cardiovascular mortality in patients with acute and chronic coronary syndrome: insights from the clinical evidence on ticagrelor.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Treatment Outcome | 2022 |
A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2022 |
Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis.
Topics: Aged; Aspirin; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Saphenous Vein; Ticagrelor; Treatment Outcome | 2022 |
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor; Vitamin K | 2022 |
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2022 |
The Applicability of Thromboelastography in Acute Ischemic Stroke: A Literature Review.
Topics: Aspirin; Blood Coagulation Disorders; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Thrombelastography; Ticagrelor | 2022 |
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2022 |
Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy.
Topics: Anticoagulants; Aspirin; Clopidogrel; Factor X; Humans; Platelet Aggregation Inhibitors; Point-of-Care Testing; Rivaroxaban; Ticagrelor; Vascular Diseases | 2022 |
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Stroke; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Regression Analysis; Rivaroxaban; Stroke; Ticagrelor | 2023 |
Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2023 |
Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Humans; Ischemic Stroke; Network Meta-Analysis; Platelet Aggregation Inhibitors; Rivaroxaban; Ticagrelor | 2023 |
Clinical Updates on Antiplatelet Therapy for Secondary Prevention in Acute Ischemic Stroke.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticagrelor | 2023 |
Refractory drug-induced systemic small-vessel vasculitis with two varied extracutaneous manifestations: a case report and review of the literature.
Topics: Aspirin; Clopidogrel; Hematuria; Humans; Immunoglobulin E; Male; Naproxen; Ticagrelor; Vasculitis; Young Adult | 2023 |
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Ticagrelor; Treatment Outcome | 2023 |
169 trial(s) available for aspirin and ticagrelor
| Article | Year |
|---|---|
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding Time; Clopidogrel; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Postmenopause; Ticagrelor; Ticlopidine | 2006 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine | 2007 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Retrospective Studies; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Double-Blind Method; Female; Humans; Interleukin-6; Male; Middle Aged; Peroxidase; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Dyspnea; Female; Heart; Humans; Lung; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Genotype; Humans; Male; Middle Aged; Pharmacokinetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States | 2011 |
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.
Topics: Adenosine; Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Diagnostic Imaging; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Health Care Costs; Hospitalization; Humans; Markov Chains; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Switzerland; Ticagrelor; Ticlopidine | 2013 |
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Cytochrome P-450 CYP2C19; Female; Humans; Male; Pilot Projects; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticagrelor | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2014 |
Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Young Adult | 2014 |
Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin.
Topics: Adenosine; Adult; Antithrombins; Aspirin; Blood Coagulation; Clopidogrel; Cross-Over Studies; Drug Synergism; Female; Healthy Volunteers; Hirudins; Humans; Male; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thrombelastography; Ticagrelor; Ticlopidine | 2014 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult | 2014 |
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Research Design; Ticagrelor; Ticlopidine; Warfarin; Young Adult | 2015 |
Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Topics: Adenosine; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Renal Dialysis; Single-Blind Method; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Secondary Prevention; Ticagrelor | 2015 |
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Topics: Adenosine; Adult; Aged; Asian People; Aspirin; Cardiac Catheterization; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Sample Size; Thrombophilia; Thrombosis; Ticagrelor | 2015 |
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Research Design; Rivaroxaban; Ticagrelor; Ticlopidine; Warfarin | 2015 |
Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
Topics: Adenosine; Adult; Animals; Aspirin; Blood Platelets; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Male; Models, Animal; ortho-Aminobenzoates; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Protein Kinase Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrimidinones; Receptors, Purinergic P2Y12; Sweden; Ticagrelor; Young Adult | 2015 |
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design.
Topics: Adenosine; Aspirin; Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Humans; Internationality; Ischemic Attack, Transient; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Research Design; Ticagrelor; Treatment Outcome | 2015 |
Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combinations; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sirolimus; Ticagrelor; Time; Treatment Outcome; Young Adult | 2016 |
Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
Topics: Adenosine; Adolescent; Adult; Area Under Curve; Aspirin; Austria; beta-Thromboglobulin; Biomarkers; Bleeding Time; Blood Platelets; Clopidogrel; Double-Blind Method; Healthy Volunteers; Hemostasis; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prothrombin; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; ROC Curve; Ticagrelor; Ticlopidine; Time Factors; Young Adult | 2016 |
Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery.
Topics: Adenosine; Aged; Aspirin; British Columbia; Chi-Square Distribution; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Early Termination of Clinical Trials; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Treatment Outcome | 2016 |
Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
Topics: Adenosine; Aged; Area Under Curve; Asian People; Aspirin; Blood Platelets; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Lower Extremity; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor; Vascular Grafting | 2016 |
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Extremities; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peripheral Arterial Disease; Prospective Studies; Severity of Illness Index; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Humans; Japan; Ticagrelor; Ticlopidine; Treatment Outcome; United States; White People | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Secondary Prevention; Stroke; Ticagrelor | 2016 |
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2016 |
Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticagrelor | 2016 |
Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
Topics: Adenosine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Aspirin; Cohort Studies; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Coronary Restenosis; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Adjustment; Ticagrelor; Treatment Outcome | 2016 |
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.
Topics: Adenosine; Adult; Aged; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolytic Agents; Humans; International Cooperation; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Growth Differentiation Factor 15; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tablets; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Topics: Adenosine; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aspirin; Blood Glucose; Cardiac Output; China; Creatine Kinase; Creatine Kinase, MB Form; Creatinine; Diabetes Mellitus, Type 2; Echocardiography; Female; Glycated Hemoglobin; Heart Atria; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke Volume; Ticagrelor; Treatment Outcome; Trimetazidine; Troponin I; Urea; Vasodilator Agents | 2017 |
Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Clopidogrel; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
Topics: Adenosine; Administration, Intravenous; Adolescent; Adult; Aspirin; Cells, Cultured; Clopidogrel; Cytokines; Drug Therapy, Combination; Endotoxemia; Endotoxins; Healthy Volunteers; Humans; Inflammation; Inflammation Mediators; Male; Netherlands; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2017 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Circulation; Coronary Vessels; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Time-to-Treatment; Treatment Outcome | 2019 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine; Warfarin | 2017 |
Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment.
Topics: Adult; Aged; Aspirin; Blood Platelets; Catechin; Clopidogrel; Coronary Stenosis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Republic of Korea; Ticagrelor; Ticlopidine | 2018 |
Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial.
Topics: Administration, Oral; Aged; Aspirin; Deglutition; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Intention to Treat Analysis; Male; Mastication; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2017 |
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Venous Thromboembolism | 2018 |
Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
Topics: Adenosine; Aspirin; Clinical Protocols; Coronary Artery Disease; Drug Therapy, Combination; England; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Research Design; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Topics: Adenosine; Aged; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Time Factors | 2018 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Female; France; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Osteoprotegerin; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Up-Regulation | 2018 |
Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; China; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909).
Topics: Aftercare; Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Saphenous Vein; Thrombosis; Ticagrelor; Vascular Patency | 2018 |
Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution.
Topics: Aged; Aspirin; Double-Blind Method; Early Termination of Clinical Trials; Endovascular Procedures; Female; Humans; Lower Extremity; Male; Middle Aged; Patient Selection; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Sample Size; Ticagrelor; Treatment Outcome; United States | 2018 |
Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
Topics: Adenosine; Adult; Aged; Aspirin; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Saphenous Vein; Ticagrelor; Vascular Patency | 2018 |
Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial.
Topics: Aspirin; Blood Flow Velocity; Blood Viscosity; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Humans; Laser-Doppler Flowmetry; Lower Extremity; Microcirculation; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Regional Blood Flow; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2018 |
DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Diamines; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Taiwan; Thiazoles; Ticagrelor | 2019 |
Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: A single-center randomized controlled trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor | 2019 |
Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Spain; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
The Acute S
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Research Design; Stroke; Ticagrelor | 2019 |
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Endpoint Determination; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk; Stroke; Ticagrelor; Time-to-Treatment | 2019 |
Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; MicroRNAs; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Stents; Taiwan; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Ticagrelor; Warfarin | 2019 |
Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Transfusion; Ticagrelor; Young Adult | 2019 |
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY).
Topics: Aspirin; Coronary Artery Disease; Drug Administration Routes; Drug Therapy, Combination; Endpoint Determination; Humans; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Research Design; Stroke; Ticagrelor | 2019 |
Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial.
Topics: Aged; Alanine; Anti-Ulcer Agents; Aspirin; Cilostazol; Clopidogrel; Cytoprotection; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Peptic Ulcer; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Quinolones; Thailand; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
Topics: Aspirin; Hemorrhage; Humans; Ischemic Attack, Transient; Mortality; Myocardial Infarction; Observer Variation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Research Personnel; Secondary Prevention; Stroke; Ticagrelor | 2019 |
Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticagrelor | 2019 |
Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial.
Topics: Acute Coronary Syndrome; Aged; Appointments and Schedules; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Italy; Male; Medication Adherence; Middle Aged; Outpatient Clinics, Hospital; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Telephone; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor | 2019 |
Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial.
Topics: Aged; Aspirin; Coronary Artery Bypass; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Male; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Ticagrelor; Treatment Outcome | 2019 |
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Stu
Topics: Acute Coronary Syndrome; Adult; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; United Kingdom | 2019 |
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Cause of Death; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor | 2019 |
Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers.
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Young Adult | 2020 |
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticagrelor | 2019 |
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Continuity of Patient Care; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Internationality; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Assessment; Severity of Illness Index; Survival Analysis; Tertiary Care Centers; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
Topics: Aged; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk; Stroke; Thrombosis; Ticagrelor; Treatment Outcome | 2019 |
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial).
Topics: Aged; Analysis of Variance; Aspirin; Asymptomatic Diseases; Coronary Angiography; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Female; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prognosis; Prospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Ticagrelor; Treatment Outcome | 2019 |
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Hemorrhagic Stroke; Humans; Ischemic Stroke; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Secondary Prevention; Sex Factors; Thrombosis; Ticagrelor | 2020 |
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Diabetes Mellitus; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2019 |
Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time; Treatment Outcome | 2020 |
Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Assessment; Sirolimus; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
Topics: Aged; Aspirin; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Death, Sudden, Cardiac; Double-Blind Method; Drug Therapy, Combination; Graft Occlusion, Vascular; Humans; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Research Design; Sample Size; Saphenous Vein; Ticagrelor; Vascular Patency | 2020 |
Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Drug Substitution; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy.
Topics: Aged; Aspirin; Blood; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Thrombosis; Ticagrelor | 2020 |
Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Stomach Ulcer; Ticagrelor; Time Factors | 2020 |
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Topics: Aspirin; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor | 2020 |
Ticagrelor With or Without Aspirin After Complex PCI.
Topics: Aged; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Risk Assessment; Risk Factors; Stents; Thromboembolism; Ticagrelor; Time Factors; Treatment Outcome; Warfarin | 2020 |
Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting.
Topics: Aged; Aspirin; Biomarkers; China; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Therapy; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Thrombosis; Ticagrelor; Time Factors; Treatment Outcome; Vascular Patency | 2022 |
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Beverages; Caffeine; Double-Blind Method; Dual Anti-Platelet Therapy; Dyspnea; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor | 2020 |
Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Saphenous Vein; Ticagrelor; Vascular Patency | 2020 |
Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial.
Topics: Aspirin; Humans; Leukocyte Count; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Stenosis; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial.
Topics: Acute Coronary Syndrome; Aged; Arachidonic Acid; Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Thromboxane A2, Prostaglandin H2; Ticagrelor | 2020 |
An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: The OPTIMA-2 randomized controlled trial.
Topics: Aged; Area Under Curve; Aspirin; Cause of Death; Combined Modality Therapy; Coronary Angiography; Creatine Kinase, MB Form; Early Termination of Clinical Trials; Factor Xa Inhibitors; Female; Fondaparinux; Humans; Male; Medical Futility; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Time Factors | 2021 |
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prognosis; Survival Rate; Thrombolytic Therapy; Ticagrelor; Time Factors | 2021 |
Fewer Subsequent Strokes with Ticagrelor Plus Aspirin than with Aspirin Alone.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Survival Rate; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Care; Renal Insufficiency, Chronic; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2021 |
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Global Health; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Sex Distribution; Sex Factors; Survival Rate; Ticagrelor; Withholding Treatment | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2021 |
A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation.
Topics: Aged; Aged, 80 and over; Anemia; Aortic Valve Stenosis; Aspirin; Blood Platelets; Clopidogrel; Comorbidity; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Spain; Ticagrelor; Time Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome | 2021 |
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI.
Topics: Age Factors; Aged; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Comparison of Ticagrelor Versus Clopidogrel on Cerebrovascular Microembolic Events and Platelet Inhibition during Transcatheter Aortic Valve Implantation.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Intracranial Embolism; Intraoperative Complications; Male; Platelet Aggregation Inhibitors; Ticagrelor; Transcatheter Aortic Valve Replacement; Ultrasonography, Doppler, Transcranial | 2021 |
Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial.
Topics: Aged; Aspirin; Dual Anti-Platelet Therapy; Female; Humans; Ischemic Stroke; Male; Middle Aged; Patient Acuity; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
Topics: Adult; Aged; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Topics: Aged; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor versus Clopidogrel in
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Ischemic Attack, Transient; Ischemic Stroke; Loss of Function Mutation; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor | 2021 |
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelo
Topics: Adenosine; Aspirin; Ataxia Telangiectasia Mutated Proteins; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2021 |
Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial.
Topics: Aspirin; Coronary Angiography; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans; Platelet Aggregation Inhibitors; Saphenous Vein; Ticagrelor; Treatment Outcome; Vascular Patency | 2022 |
Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor | 2022 |
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.
Topics: Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Renal Insufficiency, Chronic; Stroke; Ticagrelor | 2022 |
Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study).
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Epinephrine; Fibrinolytic Agents; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Multi-Omics Signatures Link to Ticagrelor Effects on Vascular Function in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Epidermal Growth Factor; Humans; Interleukin-6; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor versus aspirin 2 years after coronary bypass: Observational analysis from the TARGET trial.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Vascular Patency | 2022 |
Results from the "Me & My Heart" (eMocial) Study: a Randomized Evaluation of a New Smartphone-Based Support Tool to Increase Therapy Adherence of Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Medication Adherence; Smartphone; Ticagrelor | 2023 |
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.
Topics: Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Humans; Percutaneous Coronary Intervention; Ticagrelor | 2022 |
Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Hypertension; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Aspirin platelet reactivity on platelet function and clinical outcome in minor stroke or transient ischemic attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe
Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2022 |
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.
Topics: Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Double-Blind Method; Factor XIa; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2022 |
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor | 2022 |
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Hea
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Sex differences among patients receiving ticagrelor monotherapy or aspirin after coronary bypass surgery: A prespecified subgroup analysis of the TiCAB trial.
Topics: Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sex Characteristics; Ticagrelor; Treatment Outcome | 2023 |
A Randomized Trial of Clopidogrel vs Ticagrelor After Off-Pump Coronary Bypass.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Humans; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke.
Topics: Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Stroke; Pilot Projects; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial.
Topics: Aspirin; Blood Platelets; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2023 |
Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Genotype; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial.
Topics: Anemia; Aspirin; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Bypass; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticagrelor; Treatment Outcome | 2023 |
Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Everolimus; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Infarction; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aspirin; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Sex Characteristics; Ticagrelor | 2023 |
Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Drug-Eluting Stents; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; East Asian People; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2023 |
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2023 |
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack.
Topics: Aspirin; Body Mass Index; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Obesity; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions.
Topics: Aspirin; Heart; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
P2Y
Topics: Acute Coronary Syndrome; Aspirin; C-Reactive Protein; Colchicine; Humans; Percutaneous Coronary Intervention; Pilot Projects; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2023 |
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.
Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.
Topics: Aspirin; Drug Therapy, Combination; Dyspnea; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor Versus Clopidogrel in Minor Stroke or Transient Ischemic Attack With Intracranial Artery Stenosis: A Post Hoc Analysis of CHANCE-2.
Topics: Arteries; Aspirin; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
275 other study(ies) available for aspirin and ticagrelor
| Article | Year |
|---|---|
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
Test before you stop.
Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor | 2009 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug Therapy, Combination; Emergency Medicine; Hemorrhage; Hospitalists; Humans; Imines; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Pyridines; Receptor, PAR-1; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Approval; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States | 2011 |
Resistance to anti-platelet agents.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Aspirin dose and ticagrelor benefit in PLATO: fact or fiction?
Topics: Adenosine; Aspirin; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2010 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine | 2011 |
Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
Topics: Adenosine; Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2011 |
Ticagrelor approved for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2011 |
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug-Eluting Stents; Electrocardiography; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2012 |
Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Young Adult | 2013 |
High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Topics: Adenosine; Animals; Arachidonic Acid; Aspirin; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine; Vascular Resistance | 2013 |
Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Abnormalities; Diabetes Mellitus; Drug Interactions; Drug Labeling; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Ticagrelor; United States; United States Food and Drug Administration | 2013 |
Evidenced-based antithrombotic therapy for acute coronary syndromes.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Drug Labeling; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2013 |
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Drug Costs; Humans; Markov Chains; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Republic of Korea; Singapore; Ticagrelor; Ticlopidine | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Refuting the ticagrelor-aspirin black box warning: and proposing a ticagrelor early-PCI black box warning.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors | 2013 |
High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Aspirin; Dose-Response Relationship, Drug; Endothelium, Vascular; Male; Muscle Contraction; Myocytes, Smooth Muscle; Rats; Tail; Ticagrelor; Vasoconstriction | 2013 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Ticagrelor; Ticlopidine | 2014 |
Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Blood Transfusion; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Period; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2014 |
Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Endovascular Procedures; Female; Follow-Up Studies; Humans; Leg; Limb Salvage; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biopsy; Coronary Artery Bypass; Diagnosis, Differential; Hemoptysis; Humans; Lung; Male; Middle Aged; Platelet Aggregation Inhibitors; Pneumonia; Purinergic P2Y Receptor Antagonists; Ticagrelor; Tomography, X-Ray Computed | 2014 |
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.
Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
Short bowel syndrome and clopidogrel non-responsiveness: a new indication for platelet aggregometry?
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Short Bowel Syndrome; Ticagrelor; Ticlopidine | 2014 |
[Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality of Life; Spain; Ticagrelor; Ticlopidine; Time Factors | 2014 |
Platelet aggregation and clot formation in comatose survivors of cardiac arrest treated with induced hypothermia and dual platelet inhibition with aspirin and ticagrelor; a prospective observational study.
Topics: Adenosine; Adult; Aged; Aspirin; Blood Platelets; Coma; Combined Modality Therapy; Drug Therapy, Combination; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticagrelor | 2014 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Tirofiban; Tissue Scaffolds; Tyrosine | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Temperature effects on haemostasis in whole blood from ticagrelor- and aspirin-treated patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Combined Modality Therapy; Female; Hemostasis; Homeostasis; Humans; Hypothermia, Induced; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2015 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome; Warfarin | 2015 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Balancing the risks and benefits of dual platelet inhibition.
Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Glucosephosphate Dehydrogenase Deficiency; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2015 |
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
Topics: Adenosine; Adult; Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Rivaroxaban; Thrombin; Ticagrelor; Ticlopidine | 2015 |
Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Percutaneous dilatational tracheostomy in a patient on antiplatelet therapy with ticagrelor and Aspirin: a case report.
Topics: Adenosine; Aspirin; Blood Loss, Surgical; Dilatation; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Tracheostomy | 2015 |
Platelet inhibition with ticagrelor for left ventricular assist device thrombosis.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Heart Failure; Heart-Assist Devices; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prosthesis Design; Thrombosis; Ticagrelor; Treatment Outcome; Ventricular Function, Left | 2015 |
Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Deamino Arginine Vasopressin; Fatal Outcome; Hemostatics; Humans; Intracranial Hemorrhages; Male; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Body Mass Index; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial.
Topics: Adenosine; Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Ticagrelor; Treatment Outcome | 2015 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mortality; Neoplasms; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Sepsis; Ticagrelor; Ticlopidine | 2015 |
The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study.
Topics: Adenosine; Adenosine Diphosphate; Arachidonic Acid; Aspirin; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Ticagrelor | 2016 |
Dual antiplatelet therapy use by Canadian cardiac surgeons.
Topics: Adenosine; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Ticagrelor; Ticlopidine | 2015 |
Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
[The PEGASUS-TIMI 54 study].
Topics: Adenosine; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2015 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Odds Ratio; Patient Discharge; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polypharmacy; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Use of ticagrelor in human pregnancy, the first experience.
Topics: Adenosine; Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thromboembolism; Ticagrelor | 2015 |
Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel?
Topics: Adenosine; Aspirin; Clopidogrel; Coma; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Fatal Outcome; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pulmonary Alveoli; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Thrombosis; Ticagrelor | 2017 |
Ticagrelor in the Real World: The Midland Regional Cardiac Network Experience.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adherence; Myocardial Infarction; Patient Satisfaction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor | 2015 |
[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine | 2016 |
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2016 |
[How long should therapy last?].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; Humans; Long-Term Care; Platelet Aggregation Inhibitors; Ticagrelor | 2015 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.
Topics: Adenosine; Age Factors; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prevalence; Prognosis; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Assessment; Secondary Prevention; Spain; Ticagrelor; Time Factors | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Homeodomain Proteins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation | 2016 |
Editorial on PEGASUS - TIMI 54.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2016 |
[Dual platelet inhibition - for how long?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Evidence-Based Medicine; Guideline Adherence; Humans; Ischemic Attack, Transient; Long-Term Care; Platelet Aggregation Inhibitors; Postoperative Care; Stents; Ticagrelor | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2016 |
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2016 |
Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment.
Topics: Adenosine; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Preoperative Care; Retrospective Studies; Ticagrelor; Ticlopidine | 2016 |
Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Glucose; Blood Platelets; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Survival Analysis; Ticagrelor; Ticlopidine | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Drug Therapy, Combination; Electronic Health Records; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticagrelor; Time Factors | 2016 |
Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor for left ventricular assist device thrombosis: A new therapeutic option to be evaluated with caution.
Topics: Adenosine; Aged; Aspirin; Blood Coagulation; Cardiomyopathies; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Fibrinolytic Agents; Heart-Assist Devices; Humans; Male; Medication Therapy Management; Postoperative Complications; Risk Adjustment; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Ticagrelor; Ticlopidine; Ureteroscopy | 2016 |
NICE recommends ticagrelor with aspirin for three years post-MI.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Ticagrelor; United Kingdom | 2016 |
In acute stroke or TIA, ticagrelor did not differ from aspirin for a composite of stroke, MI, or death at 90 days.
Topics: Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2016 |
Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
Topics: Adenosine; Aspirin; Cardiology; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Italy; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Societies, Medical; Thrombosis; Ticagrelor | 2017 |
Spontaneous coronary artery dissection in a young woman with polycystic ovarian syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Chest Pain; Coronary Angiography; Coronary Vessel Anomalies; Coronary Vessels; Electrocardiography; Female; Humans; Platelet Aggregation Inhibitors; Polycystic Ovary Syndrome; Purinergic P2Y Receptor Antagonists; Ticagrelor; Vascular Diseases | 2017 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)".
Topics: Adenosine; Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2017 |
Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcom
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2017 |
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Medication Therapy Management; Patient Discharge; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Survival Analysis; Ticagrelor; Ticlopidine | 2017 |
Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Warfarin | 2017 |
Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Case-Control Studies; Coronary Artery Disease; Drug Therapy, Combination; Half-Life; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Thienopyridines; Thrombopoiesis; Ticagrelor; Young Adult | 2017 |
In the news: ISC 2017 - getting the heads-up on stroke.
Topics: Aspirin; Double-Blind Method; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2017 |
Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin.
Topics: Adenosine; Adenosine Diphosphate; Animals; Antibodies, Neutralizing; Antidotes; Aspirin; Biotinylation; Blood Pressure; Broadly Neutralizing Antibodies; Hemorrhage; Hemostasis; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Swine; Ticagrelor; Time Factors | 2017 |
Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™.
Topics: Adenosine; Aged; Aspirin; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2017 |
Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Reproducibility of Results; Signal Transduction; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Heterozygote; Homozygote; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome; Vitamin D Deficiency; Vitamin D-Binding Protein | 2017 |
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy?
Topics: Aspirin; Belgium; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescription Drugs; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2017 |
Investigating therapeutic usage of combined Ticagrelor and Aspirin through solid-state and analytical studies.
Topics: Adenosine; Aspirin; Calorimetry, Differential Scanning; Chromatography, High Pressure Liquid; Drug Combinations; Drug Stability; Mass Spectrometry; Platelet Aggregation Inhibitors; Powder Diffraction; Spectroscopy, Fourier Transform Infrared; Thermogravimetry; Ticagrelor; X-Ray Diffraction | 2017 |
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome
Topics: Adenosine; Aged; Aspirin; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Purinergic P2Y Receptor Antagonists; Risk; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
The impact of CYP2C19*2, CYP4F2*3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P450 Family 4; Female; Humans; Hydroxyeicosatetraenoic Acids; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Pharmacovigilance; Platelet Aggregation Inhibitors; Pyridines; Ticagrelor | 2017 |
Microfludic platforms for the evaluation of anti-platelet agent efficacy under hyper-shear conditions associated with ventricular assist devices.
Topics: Adenosine; Aspirin; Drug Evaluation, Preclinical; Heart-Assist Devices; Lab-On-A-Chip Devices; Platelet Aggregation Inhibitors; Shear Strength; Sonication; Ticagrelor | 2017 |
A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study.
Topics: Absorbable Implants; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Design; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Ticagrelor | 2018 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
Topics: Adenosine; Adenosine Diphosphate; Aged; Anemia; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine | 2018 |
[Clinical effectiveness and safety of ticagrelor in patients after PCI because of acute non ST segment elevation myocardial infarction].
Topics: Adenosine; Aspirin; China; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Coronary Vessels; Disease-Free Survival; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Risk Factors; Thrombectomy; Ticagrelor; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2017 |
Platelet responses to pharmacological and physiological interventions in middle-aged men with different habitual physical activity levels.
Topics: Aspirin; Blood Platelets; Cross-Sectional Studies; Epoprostenol; Exercise; Femoral Artery; Habits; Healthy Lifestyle; Humans; Lower Extremity; Male; Middle Aged; Nitric Oxide; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Regional Blood Flow; Sedentary Behavior; Ticagrelor; Ultrasonography, Doppler; Vasodilation | 2018 |
Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Receptor, Adenosine A2A; Ticagrelor | 2018 |
Bleeding frequency of patients taking ticagrelor, aspirin, clopidogrel, and dual antiplatelet therapy after tooth extraction and minor oral surgery.
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Tooth Extraction | 2018 |
Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms.
Topics: Aspirin; Dual Anti-Platelet Therapy; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Ticagrelor; Vascular Surgical Procedures | 2019 |
Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
Topics: Aged; Asia; Aspirin; Clopidogrel; Drug Administration Schedule; Female; Humans; Incidence; Inpatients; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome | 2018 |
Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; France; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Registries; Risk Factors; Secondary Prevention; Sex Factors; Ticagrelor | 2018 |
In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Corona
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality Improvement; Registries; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
The effects of aspirin and ticagrelor on Toll-like receptor (TLR)-mediated platelet activation: results of a randomized, cross-over trial.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Signal Transduction; Ticagrelor; Toll-Like Receptors | 2019 |
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Prescriptions; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Treatment Outcome; United States | 2018 |
There seems to be a low risk of experiencing postoperative bleeding in patients undergoing dental extractions or minor oral surgery who continue using antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Ticagrelor; Tooth Extraction | 2018 |
Prescribing patterns of oral antiplatelets in Wales: evolving trends from 2005 to 2016.
Topics: Administration, Oral; Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Wales | 2018 |
Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Registries; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2018 |
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects.
Topics: Acute Coronary Syndrome; Aftercare; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hospitalization; Humans; Italy; Male; Medication Adherence; Middle Aged; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor | 2019 |
Ticagrelor not superior to DAPT after PCI.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2018 |
The association between a three-day ticagrelor discontinuation and perioperative bleeding complications.
Topics: Aged; Aspirin; Blood Loss, Surgical; Cardiac Surgical Procedures; Coronary Artery Bypass; Female; Heart Valves; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Ticagrelor; Time Factors | 2019 |
The Role of OCT Guidance for Antiplatelet Therapy.
Topics: Aspirin; Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Tomography, Optical Coherence | 2018 |
Stenting for Aorto-Ostial In-Stent Restenosis via Side Strut of an Excessively Protruding Stent Guided by Intracoronary Imaging.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Stents; Ticagrelor | 2018 |
Commentary: Dual antiplatelet therapy after coronary artery bypass graft surgery: Fewer stones remain unturned.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Platelet Aggregation Inhibitors; Ticagrelor | 2019 |
Effect of P2Y
Topics: Adenosine Monophosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2019 |
Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Treatment Outcome | 2018 |
New opportunities to optimize antithrombotic therapy for secondary stroke prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2019 |
Number Needed to Treat: Conveying the Likelihood of a Therapeutic Effect.
Topics: Aspirin; Coronary Artery Bypass; Probability; Saphenous Vein; Ticagrelor | 2019 |
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Europe; Female; Hemorrhage; Humans; Male; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Registries; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Stents; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction.
Topics: Aged; Anterior Wall Myocardial Infarction; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Echocardiography; Female; Follow-Up Studies; Heart Diseases; Heart Ventricles; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor; Treatment Outcome; Turkey | 2019 |
Dual platelet antiaggregation therapy after myocardial revascularization surgery.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Graft Occlusion, Vascular; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome; Vascular Patency | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Propensity Score; Retrospective Studies; Stroke; Ticagrelor | 2019 |
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Europe; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Registries; Retrospective Studies; Ticagrelor; Treatment Outcome | 2019 |
Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor | 2019 |
The impact of
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P450 Family 4; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Stents; Ticagrelor | 2019 |
The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy.
Topics: Aspirin; Coronary Artery Bypass; Fibrinolytic Agents; Humans; Myocardial Infarction; Ticagrelor | 2019 |
Course of platelet miRNAs after cessation of P2Y12 antagonists.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; MicroRNAs; Middle Aged; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2019 |
Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2019 |
Dyspnoea in the GLOBAL LEADERS trial - Authors' reply.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Dyspnea; Humans; Ticagrelor | 2019 |
Dyspnoea in the GLOBAL LEADERS trial.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Dyspnea; Humans; Ticagrelor | 2019 |
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
Topics: Aged; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2019 |
Myocardial infarction with nonobstructive coronary arteries in a young woman: the key role of optical coherence tomography.
Topics: Abciximab; Adult; Aspirin; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Female; Humans; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Tomography, Optical Coherence | 2019 |
Contemporary audit of antiplatelet therapy prescribing patterns following coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Humans; Length of Stay; Male; New Zealand; Platelet Aggregation Inhibitors; Postoperative Care; Practice Patterns, Physicians'; Ticagrelor | 2019 |
The association of P2Y
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Extracellular Vesicles; Female; Humans; Male; MicroRNAs; Middle Aged; Phosphatidylserines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Short DAPT after DES: P2Y12 monotherapy is in, aspirin is out!
Topics: Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2019 |
Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; Deprescriptions; Drug Substitution; Dual Anti-Platelet Therapy; Dyspnea; Factor Xa Inhibitors; Female; Humans; Male; Non-ST Elevated Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Prime time for ticagrelor monotherapy.
Topics: Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2019 |
Aspirin-Free Strategies After PCI: Still Not Out of the Twilight.
Topics: Aspirin; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2019 |
Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study.
Topics: Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor | 2020 |
Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty?
Topics: Aspirin; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2019 |
Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardial Infarction; Stroke; Ticagrelor; Treatment Outcome | 2020 |
Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Dual Anti-Platelet Therapy; Female; Homocysteine; Humans; Hyperhomocysteinemia; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Reproducibility of Results; Retrospective Studies; Risk Assessment; Ticagrelor; Treatment Outcome | 2020 |
[PEGASUS or COMPASS? A guide for a wise clinical choice.]
Topics: Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Registries; Risk; Rivaroxaban; Ticagrelor | 2019 |
Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion.
Topics: Animals; Apoptosis; Aspirin; Atrial Natriuretic Factor; Disease Models, Animal; Drug Therapy, Combination; Endoglin; Fibrosis; Gene Expression Regulation; Myocardial Infarction; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proto-Oncogene Proteins c-kit; Rats; Rats, Sprague-Dawley; Stem Cells; Ticagrelor; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Assessment of platelet function after discontinuation of ticagrelor.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticagrelor | 2020 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Thromboembolism; Ticagrelor; Treatment Outcome; Warfarin | 2020 |
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Hemorrhage; Humans; Ticagrelor | 2020 |
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Dual Anti-Platelet Therapy; Humans; Molecular Diagnostic Techniques; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation Inhibitors; Predictive Value of Tests; Quality-Adjusted Life Years; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Designing Human In Vitro Models for Drug Development.
Topics: Aspirin; Blood Platelets; Drug Development; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
After PCI and 3 mo of DAPT, ticagrelor for 12 mo reduced bleeding vs continued DAPT and did not increase ischemic events.
Topics: Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Gastrointestinal Hemorrhage; Hemorrhage; Heparin; Hirudins; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Stents; Ticagrelor; Urologic Diseases | 2020 |
Efficacy of Cangrelor as Bridging Therapy Post PCI.
Topics: Adenosine Monophosphate; Aged; Aspirin; Colectomy; Colonic Neoplasms; Drug-Eluting Stents; Factor Xa Inhibitors; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridones; Thrombosis; Ticagrelor | 2020 |
Ticagrelor with or without Aspirin after PCI.
Topics: Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Ticagrelor with or without Aspirin after PCI.
Topics: Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Ticagrelor with or without Aspirin after PCI. Reply.
Topics: Aspirin; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Drug-eluting Vein Graft with Acetylsalicylic Acid-Ticagrelor-Unfractionated Heparin Complex Inhibits Early Graft Thrombosis
Topics: Animals; Anticoagulants; Aspirin; Coronary Artery Bypass; Disease Models, Animal; Graft Enhancement, Immunologic; Heparin; Pathology; Platelet Aggregation Inhibitors; Poloxamer; Rats; Thrombosis; Ticagrelor; Veins | 2020 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal Microbiome; Humans; Intestines; Male; Methylamines; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Thrombosis; Ticagrelor; Time Factors; Treatment Outcome; United States; Up-Regulation | 2020 |
Twilight, the Dawn of a New Era of Aspirin-Free PCI?
Topics: Aspirin; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies.
Topics: Antigens, Human Platelet; Arginine; Aspirin; Autoantibodies; Combined Modality Therapy; Coronary Thrombosis; Drug Substitution; Drug Therapy, Combination; Eptifibatide; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Purpura, Thrombocytopenic, Idiopathic; Shock, Cardiogenic; ST Elevation Myocardial Infarction; Stents; Sulfonamides; Thrombectomy; Thrombolytic Therapy; Thrombosis; Ticagrelor; Warfarin | 2020 |
Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels.
Topics: Adult; Aspirin; Coronary Disease; Creatine Kinase, MB Form; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Ticagrelor | 2020 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Stroke; Survival Rate; Ticagrelor | 2020 |
Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Treatment Outcome | 2020 |
Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Genotype; Glutathione S-Transferase pi; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Polymorphism, Single Nucleotide; Receptors, Cell Surface; Retrospective Studies; Ticagrelor | 2020 |
Duration of antiplatelet therapy after complex PCI in the TWILIGHT-COMPLEX trial: the Goldilocks dilemma.
Topics: Aspirin; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Major Bleeding after Surgical Revascularization with Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Databases, Factual; Dual Anti-Platelet Therapy; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reoperation; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Therapy; Endarterectomy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2020 |
Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Artery Disease; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2021 |
Ticagrelor monotherapy in patients undergoing percutaneous coronary intervention for bifurcation lesions.
Topics: Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2020 |
Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
Topics: Adult; Aspirin; Humans; Ischemic Attack, Transient; Odds Ratio; Platelet Aggregation Inhibitors; Pragmatic Clinical Trials as Topic; Randomized Controlled Trials as Topic; Research Design; Stroke; Ticagrelor; Treatment Outcome | 2020 |
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Dual Anti-Platelet Therapy; Female; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Recurrence; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
Topics: Aspirin; Data Interpretation, Statistical; Dual Anti-Platelet Therapy; Endpoint Determination; Equivalence Trials as Topic; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Research Design; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Time Factors; Treatment Outcome | 2020 |
Supplemental Fibrinogen Restores Platelet Inhibitor-Induced Reduction in Thrombus Formation without Altering Platelet Function: An In Vitro Study.
Topics: Aged; Aspirin; Calcium Signaling; Female; Fibrinogen; Hemorheology; Heparin; Hirudins; Humans; In Vitro Techniques; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Thrombosis; Ticagrelor; Tirofiban | 2020 |
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis.
Topics: Adult; Aspirin; Biosynthetic Pathways; Blood Platelets; Drug Discovery; Humans; Hydroxyeicosatetraenoic Acids; Lipidomics; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandins; Ticagrelor; Young Adult | 2020 |
The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention.
Topics: Aspirin; Heparin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2021 |
Antiplatelet Agents Added to Aspirin: No Benefit for SVG Patency After CABG.
Topics: Aspirin; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
P2Y
Topics: Aspirin; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
Reply: P2Y
Topics: Aspirin; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
In ACS treated with drug-eluting stents and 3 mo of DAPT, ticagrelor monotherapy reduced clinical events at 1 y vs. DAPT.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. Reply.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2020 |
The long journey of individualizing antiplatelet therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; Cause of Death; Clopidogrel; Databases, Factual; Dyspnea; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Propensity Score; Purinergic P2Y Receptor Antagonists; Recurrence; Republic of Korea; Retrospective Studies; Stroke; Ticagrelor; United States | 2020 |
Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans.
Topics: Adult; Aged; Aspirin; Black or African American; Blood Platelets; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; White People | 2021 |
When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y
Topics: Aspirin; Blood Platelets; Humans; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2020 |
In acute ischemic stroke or TIA, adding ticagrelor to aspirin reduced stroke or death and increased severe bleeding.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Ischemic Stroke; Stroke; Ticagrelor | 2020 |
Differences in thromboembolism after stent-assisted coiling for unruptured aneurysms between aspirin plus clopidogrel and ticagrelor.
Topics: Adult; Aged; Aspirin; Clopidogrel; Diffusion Magnetic Resonance Imaging; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Stents; Thromboembolism; Ticagrelor | 2020 |
Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy.
Topics: Aspirin; Blood Platelets; Dual Anti-Platelet Therapy; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2022 |
Acute coronary syndromes: summary of updated NICE guidance.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Cardiac Rehabilitation; Clopidogrel; Combined Modality Therapy; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Secondary Prevention; ST Elevation Myocardial Infarction; Ticagrelor; United Kingdom | 2021 |
Late Stent Thrombosis After Drug-Coated Balloon Coronary Angioplasty for In-Stent Restenosis.
Topics: Acute Disease; Adult; Aftercare; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Occlusion; Coronary Restenosis; Cytochrome P-450 CYP2C19; Dual Anti-Platelet Therapy; Female; Fibrinolytic Agents; Humans; Integrin alpha2; Mutation; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stents; Thrombectomy; Thrombosis; Ticagrelor; Tirofiban; Treatment Outcome | 2021 |
The effect of de-escalation of P2Y12 receptor inhibitor therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: A nationwide cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Dual Anti-Platelet Therapy; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Young Adult | 2021 |
Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke.
Topics: Animals; Aspirin; Brain Ischemia; Clopidogrel; Inflammasomes; Ischemic Stroke; Isoindoles; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Phenylbutyrates; Pyroptosis; Rats; Reperfusion Injury; Stroke; Ticagrelor | 2021 |
Creatine kinase and bleeding in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Creatine Kinase; Dual Anti-Platelet Therapy; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor | 2021 |
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction.
Topics: Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus; Dual Anti-Platelet Therapy; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; ST Elevation Myocardial Infarction; Stroke Volume; Ticagrelor; Treatment Outcome | 2021 |
Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry.
Topics: Aged; Aspirin; Clinical Decision-Making; Clinical Trials as Topic; Drug Administration Schedule; Dual Anti-Platelet Therapy; Female; Hemorrhage; Hospital Mortality; Humans; Italy; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2021 |
Successful Therapy With Ticagrelor in Three-Vessel Stent Thrombosis Related to Clopidogrel Resistance.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Dual Anti-Platelet Therapy; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticagrelor | 2021 |
Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI.
Topics: Acute Coronary Syndrome; Adenosine; Arachidonic Acid; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2021 |
Spontaneous spinal epidural hematoma associated with antiplatelet therapy with aspirin and ticagrelor.
Topics: Aspirin; Hematoma, Epidural, Spinal; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2021 |
Benefits of Ticagrelor Plus Aspirin According to Diabetes-Related Factors: A Complex Equation.
Topics: Aspirin; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes.
Topics: Aged; Aspirin; Coronary Artery Bypass; Drainage; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Stents; Thoracic Cavity; Thrombosis; Ticagrelor | 2021 |
Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Cerebrovascular Disorders; Coronary Artery Disease; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Network Meta-Analysis; Platelet Aggregation Inhibitors; Secondary Prevention; Stroke; Ticagrelor | 2021 |
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events.
Topics: Acute Coronary Syndrome; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2021 |
Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cohort Studies; Coronary Artery Bypass; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Propensity Score; Prospective Studies; Sweden; Ticagrelor | 2021 |
Prognostic value of haemoglobin drop in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Dual Anti-Platelet Therapy; Female; Hemoglobins; Humans; Male; Middle Aged; Mortality; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ticagrelor | 2021 |
FDA PLATO deaths list challenges aspirin dose-ticagrelor interaction.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial.
Topics: Acute Coronary Syndrome; Aspirin; Carbidopa; Drug Combinations; Humans; Levodopa; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China.
Topics: Aged; Algorithms; Asian People; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Health Behavior; Hemorrhage; Humans; Male; Middle Aged; Pharmacogenetics; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Sociodemographic Factors; Ticagrelor; Ticlopidine | 2022 |
Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting.
Topics: Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endovascular Procedures; Femoral Artery; Humans; Platelet Aggregation Inhibitors; Protamines; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2022 |
Ticagrelor versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Thromboembolism; Ticagrelor; Treatment Outcome | 2022 |
Sex Difference in Bleeding Risk With P2Y12 Inhibitor Agents After Percutaneous Coronary Intervention-Reply.
Topics: Aspirin; Female; Humans; Male; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Sex Characteristics; Ticagrelor | 2022 |
The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Tirofiban; Treatment Outcome | 2022 |
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Humans; Obesity; Overweight; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2023 |
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Topics: Animals; Anticoagulants; Aspirin; Factor XIa; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Rabbits; Thrombin; Thrombosis; Ticagrelor | 2022 |
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Cyclooxygenase 1; Fibrinolytic Agents; Humans; Peptides; Platelet Aggregation Inhibitors; Prospective Studies; Receptors, Thrombin; Rivaroxaban; Thrombin; Thromboplastin; Ticagrelor | 2022 |
Does thromboelastography predict bleeding in patients treated with clopidogrel or ticagrelor in off-pump coronary artery bypass grafting?
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Thrombelastography; Ticagrelor | 2022 |
Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Ischemic Attack, Transient; Ischemic Stroke; Male; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2022 |
Ticagrelor and Endothelial Function: An Effect That Persists Far From the Acute Phase and in Monotherapy.
Topics: Aspirin; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro.
Topics: Antibodies, Neutralizing; Aspirin; B7-H1 Antigen; Blood Platelets; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Humans; Immune Checkpoint Inhibitors; Immune Checkpoint Proteins; Interferon-gamma; Neoplasms; Platelet Aggregation Inhibitors; Ticagrelor; United States | 2022 |
Dual antiplatelet use in the management of COVID-19 associated acute ischemic stroke reocclusion.
Topics: Aspirin; Brain Ischemia; COVID-19; Humans; Ischemic Stroke; Middle Aged; Retrospective Studies; SARS-CoV-2; Stroke; Thrombectomy; Ticagrelor; Treatment Outcome | 2023 |
An antiplatelet response gene expression signature is associated with bleeding.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Transcriptome; Treatment Outcome | 2023 |
Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Topics: Acute Coronary Syndrome; Aspirin; Australia; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor.
Topics: Animals; Aspirin; Dialysis Solutions; Humans; Infarction; Ischemia; Rats; Ticagrelor | 2023 |
Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; China; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2022 |
Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor.
Topics: Adenosine Diphosphate; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Cost-effectiveness of testing for CYP2C19 loss-of-function carriers following transient ischemic attack/minor stroke: A Canadian perspective.
Topics: Aspirin; Canada; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Quality of Life; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine | 2023 |
Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs.
Topics: Aminopyridines; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Morpholines; Oxazines; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Pyridines; Pyrimidines; Thrombosis; Ticagrelor | 2022 |
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Secondary Prevention; Ticagrelor; Treatment Outcome | 2022 |
Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2022 |
Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Cholesterol; Clopidogrel; Cohort Studies; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Preoperative treatment with clopidogrel and ticagrelor on bleeding complications in off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Retrospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Impact of Close Surveillance on Dual-Antiplatelet Therapy Compliance in Myocardial Infarction Patients Post-Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Ticagrelor; Treatment Outcome | 2023 |
Aspirin and P2Y12 inhibitors in treating COVID-19.
Topics: Aspirin; Blood Platelets; COVID-19; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2023 |
Short DAPT for PCI after CABG: ready for prime time
Topics: Aspirin; Coronary Artery Bypass; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery-Reply.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagrelor; Veins | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagrelor; Veins | 2022 |
Ticagrelor Aspirin vs Clopidogrel Aspirin in
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Neoplasm Recurrence, Local; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study.
Topics: Adenosine; Aspirin; Clopidogrel; Fibrinogen; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Ticagrelor versus clopidogrel dual antiplatelet therapy for unruptured intracranial aneurysms treated with flowdiverter.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Retrospective Studies; Thromboembolism; Ticagrelor; Treatment Outcome | 2023 |
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; COVID-19; Drug Therapy, Combination; Humans; Male; Pandemics; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2022 |
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Stroke; Ticagrelor | 2023 |
Effect of pathological high shear exposure time on platelet activation and aggregation.
Topics: Aspirin; Blood Platelets; Constriction, Pathologic; Fibrinogen; Humans; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Tirofiban; von Willebrand Factor | 2023 |
[Debate on antiplatelet monotherapy: Why not leaving out good old aspirin for clopidogrel or ticagrelor in monotherapy in chronic coronary syndromes after a percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Rectus Sheath Hematoma in a Patient with Dual-Antiplatelet Therapy Including Ticagrelor: A Case Report.
Topics: Abdominal Pain; Acute Coronary Syndrome; Aged, 80 and over; Aspirin; Hematoma; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2023 |
The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study.
Topics: Acute Coronary Syndrome; Aspirin; East Asian People; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Salicylic Acid; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome | 2023 |
A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cohort Studies; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor | 2023 |
Pathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report.
Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Comparison of Ticagrelor Monotherapy and Ticagrelor Plus Aspirin Among Patients With Acute Coronary Syndrome Combined With High-Risk of Gastrointestinal Bleeding After Percutaneous Coronary Intervention: A Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2023 |
Effects of Antiplatelet Drugs on Platelet-Dependent Coagulation Reactions.
Topics: Alprostadil; Aspirin; Blood Coagulation; Blood Platelets; Collagen; Fibrin; Humans; Platelet Aggregation Inhibitors; Thrombin; Ticagrelor | 2023 |
Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Plaque, Atherosclerotic; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; ST Elevation Myocardial Infarction; Thrombosis; Ticagrelor | 2023 |
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Treatment Outcome | 2023 |
Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Arachidonic Acid; Aspirin; Clopidogrel; Gelsolin; Humans; Mean Platelet Volume; MicroRNAs; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke Volume; Ticagrelor; Ventricular Function, Left | 2023 |
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2023 |
Ticagrelor vs Clopidogrel in Acute Myocardial Infarction Patients With a History of Ischemic Stroke.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor | 2023 |